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The Anticoagulant Activity of Some Qarrageenans
Summary
Introduction
The biological properties of the carrageenans and of certain 
other sulphated polysaccharides have been reviewed, and since the 
object of this work was to study the anticoagulant activity of 
intravenously-administered carrageenan, current theory of blood 
coagulation has been outlined. For comparison, the properties and 
mode of anticoagulant action of heparin have been reviewed*
Experimental
The practical work is reported in three sections.
A preliminary section deals with the anticoagulant activity, 
in the rabbit, of a number of carrageenans, fractionated where 
appropriate, into k- and X-components. Doses fatal to rabbits within 
24 hours are also recorded since many of these carrageenans were 
acutely toxic when administered intravenously. Frequently, lethal 
doses were close to anticoagulant doses and there seemed, from the 
preliminary work, reason to believe that the anticoagulant effect of 
these substances was associated with their toxic manifestations.
2*
In the main section, a more detailed study of the anticoagulant 
activity of the k- and X -carrageenans of Chondrus crispus from four 
habitats, of the carrageenan from Folyides rotundus and of degraded 
carrageenan from Eucheuma spinosum, is reported, and comparisons are 
made with heparin. Tests of clotting function were used to localise 
the anticoagulant activity in the clotting mechanism.
The results of some preliminary experiments to determine the 
effects of carrageenan on platelets and fibrinogen are reported because 
it is believed that the toxicity of certain high molecular weight 
sulphated polysaccharides is caused by fibrinogen precipitation 
complicated by platelet and blood cell involvement in the precipitated 
complex, so blocking important vascular beds. These preliminary 
results give adequate confirmation that the toxic carrageenans behave 
similarly, while the non-toxic carrageenan does not.
Conclusions
The results of this study confirm the belief that the anti­
coagulant activity of X -carrageenan is greater than that of k-carrageenan 
and indicate that this holds for Chondrus carrageenans in general, in 
spite of marked variations in the properties of different carrageenans. 
They also show that the relationship between activity and ester sulphate, 
previously believed to be critical, is not a simple one, although the
X -carrageenan from any seaweed is always higher in sulphate content 
than the corresponding k-carrageenan. Of all the carrageenans examined, 
that of Folyides showed greatest activity. Degraded Eucheuma carrageenan 
was the least toxic of those examined and of lowest molecular weight; 
hut although of high sulphate content, a much higher dose was required 
to show anticoagulant activity than of other carrageenans.
The anticoagulant activity of the carrageenans can he detected 
at all stages of the clotting reaction examined, and this supports the 
view that a. non-specific complexing reaction with many plasma proteins 
is involved, in contrast to the more localised action of heparin.
(D
U1
CD
o
H-
w
X
s
H*
(D
4
O
o
o
o
Hj
H
O
01
H*
cf
c+
(D
CD
H-
H-
DO
O#
ct"
>
M
H-
O
0)
cf-
H*
O
O'
A C K N O V / L E D G E M E N T S
I wish to thank Dr. TL Anderson most sincerely for his help, 
guidance and encouragement throughout the course of this work.
I also express my thanks to Professor J. B; Stenlake for his 
interest, for the opportunity to pursue this work and for the 
facilities to do so.
I am very grateful to Mrs. P.E.A. Wilson and to Miss J. E.
Barthill for technical assistance which has been given so willingly# 
My thanks are also extended to all members of the staff of the 
Animal House for their care and attention of the laboratory 
animals.
The carrageenan extracts were prepared by Dr. E. T. Dewar 
and his colleagues of the Arthur D. Little Research Institute, 
îiîidlothian, and I am grateful to them for kindly supplying them.
The Anticoagulant Activity of Some Carrageenans
Introduction
The biological properties of the carrageenans and of certain othe 
sulphated polysaccarides have been reviewed, and since the object of 
this work was to study the anticoagulant activity of intravenously- 
administered carrageenan, current theory of blood coagulation has been 
outlined. Por comparison, the properties and mode of anticoagulant 
action of heparin have been reviewed.
Experimental
The practical work is reported in three sections.
A preliminary section deals with the anticoagulant activity, in 
the rabbit, of a number of carrageenans, fractionated where appropriât 
into k“ and A -components. Doses fatal to rabbits within 24 hours ar 
also recorded since many of these carrageenans were acutely toxic when 
administered intravenously. Frequently, lethal doses were close to 
anticoagulant doses and there seemed, from the preliminary work, roaso 
to believe that the anticoagulant effect of these substances was assoc 
iated with their toxic manifestations.
In the main section, a more detailed study of the anticoagulant 
activity of the k- and X -carrageenans of Chondrus crispus from four 
habitats, of the carrageenan from Polyides rotundus and of degraded 
carrageenan from Eucheuma spinosum, is reported, and comparisons are 
made with heparin. Tests of clotting function were used to localise 
the anticoagulant activity in the clotting mechanism.
The results of some preliminary experiments to determine the 
effects of carrageenan on platelets and fibrinogen are reported 
because it is believed that the toxicity of certain high molecular 
weight sulphated polysaccharides is caused by fibrinogen precipit­
ation complicated by platelet and blood cell involvement in the 
precipitated complex, so blocking important vascular beds. These 
preliminary results give adequate confirmation that the toxic 
carrageenans behave similarly, while the non-toxic carrageenan does 
not.
Conclusions
The results of this study confirm the belief that the anti­
coagulant activity of A -carrageenan is greater than that of k- 
carrageenan and indicate that this holds for Chondrus carrageenans 
in general, in spite of marked variations in the properties of 
different carrageenans. They also show that the relationship 
between activity and ester sulphate, previously believed to be 
critical/
11
/critical, is not a simple one, although the A-carrageenan from any 
seaweed is always higher in sulphate content than the corresponding 
k“carrageenan. Of all the carrageenans examined, that of Polyides 
showed greatest activity. Degraded Eucheuma carrageenan was the 
least toxic of those examined and of lowest molecular weight, hut 
although of high sulphate content, a much higher dose was required to 
show anticoagulant activity than of other carrageenans.
The anticoagulant activity of the carrageenans can he detected 
at all stages of the clotting reaction examined, and this supports 
the view that a non-specific complexing reaction with many plasma 
proteins is involved, in contrast to the more localised action of 
heparin.
CONTENTS,
INTEODUCTION,
PAGE,
THE CAIÎHAGEENANS 1
Biological Properties of Carrageenans 5
BLOOD COAGULATION 12
Blood Coagulation Factors 18
HBPâPiIN 26
Chemical and General Properties 26
Mode of Anticoagulant Action 29
AIMS OF THE PRESENT STUDY 32
EXPEEII.iBMTAL.
PART 1 - PRELIMINARY EXPERIMENTS TO DETERMINE 34
SUITABLE DOSAGE
PART 2 - THE ANTICOAGULANT ACTION OF VARIOUS 38
CARRAGEENANS 
PREPARATION OF HE/i.GENTS
SODIUM CITRATE SOLUTION 40
CALCIUM CHLORIDE SOLUTION 40
SODIUM CHLORIDE SOLUTION 40
OTHiEN'S VERONAL BUFFER 40
THROMBIN SOLUTION 40
PAGE.
BRAIH TER0MB0PBA8TIB 41
Acetone-dried brain (thromboplastin source) 4I
Saline suspension of acetone-dried brain 42
Preliminary extraction experiments 42
PLATELET SUBSTITUTE 43
FIBRINOGEN 44
Preparation of Alumina Suspension 44
Preparation of Phosphate Buffer 45
Fibrinogen 45
HEPARIN 47
PENTOBiiRBITONE 47
GLASSWi\RE 47
PREPiVRATION OF CARRAGEENANS
Chondrus carrageenans 48
Method of Extraction and Fractionation 48
Polyides rotundus 49
Carrageenan from Eucheuma spinosum 49
Degraded X-carrageenan 50
Rees’ pure X-oarrageenan 50
TESTS OF CLOTTING FUNCTION
1. %ole Blood Coagulation Test 51
2. Thrombin Generation Test 51
Thrombin-Pibrinogen Dilution Curve 52
PAGE
3. Thrombin Time 53
4. Reoalcification Time 53
5. One-stage Prothrombin Test 54
60 Two-stage Prothrombin Test 54
7. Prothrombin Consumption Test 55
8. Thromboplastin Generation Test 57
PART 3 - IN VITRO PLATELET COUNTS ilND FIBRINOGEN 59
PRECIPITATION TESTS 
PLATELET COUNTING 59
Approximate physiological concentration effects 60
Platelet counts (in vivo) 6l
REACTION OF CARRAGEEThTN VŒTH FIBRINOGEN SOLUTIONS 6l
DISCUSSION.
PiiRT 1 - PREXJMINARY EXPERIÎÜENTS - DOSAGE AND TOXICITY 63
PART 2 - BLOOD COAGULATION TESTS 65
lo RTiole Blood Coagulation Test 65
2o Thrombin Generation Test 66
3. Thrombin Time 67
4. Recalcification Time 68
5. One-stage Prothrombin Test 69
6. Two-stage Prothrombin Test 70
7. Pr o thrombin C on sumpt i on Test - - J2
8. Thromboplastin Generation Test 73
Pentobarbitone
PAGE
GENERAI, DISCUSSION
Anticoagulant Activity 76
Localisation of Interference in Blood Coagulation 77
Intravenous Toxicity of Carrageenans 80
RESULTS.
TABLE A PROPERTIES OF CARRAGEENANS 84
TABLE 1 AVERAGE COAGULATION TIMES 86
TABLE 2 COMPARISON OF FATAL DOSES 87
TiiBLE 3 ■MAXIMUM ANTICOAGULANT EFFECT 88
TABLE 4 SCREENING TEST FOR PLATELET SUBSTITUTE 89
TABLE 5 UaOLE BLOOD COAGULATION TEST 90
TABLE 6 THROMBIN TIME 93
TABLE 7 DECALCIFICATION TIME 95
TABLE 8 ONE-STAGE PROTHROMBIN TEST 97
TAiBLE 9 TLO-STAGE PROTHROMBIN TEST 99
TABLE 10 PROTHROMBIN CONSUMPTION TEST 101
TABLE 11 THROMBOPLASTIN GENERATION TEST IO4
TIÆLE 12 PLATELET COUNTS (iN VITRO) 111
TABLE 12A PLATELET COUNTS AT APPROXIMfiTE 112
PHYSIOLOGICAL CONCENTRATIONS 
TABLE 12B PLATELET COUNTS (IN VIVO) 112
TABLE 13 FIBRINOGEN - GiDSHAGEENAN REACTIONS 113
PAGE,
APPENDIX 1
THROMBIN - FIBRINOGEN CURVE 114
THROMBIN GENER/iTIOH TEST 115
REFERENCES 136
I N T R O D U C T I O N
1.
'PHE GARRilGEMAIXS
Carrageenan is the name applied to a mixture of water-extraotable 
galactan sulphuric acid esters of certain species of red marine algae 
(Rhodophyceae), e.g. Chondrus, Gigartina, Iridaea and Eucheuma species, 
in which they are found as cell-wall constituents. The term 
"carrageenan” was originally derived from its principal market site, 
Carrageen, in Ireland and even yet, Chondrus crispus is often referred 
to as Irish Moss. It has now become clear that carrageenan as a total 
extract is not one single substance, as has often been assumed in the 
literature, but is a mixture of sulphated polysaccharides. They are 
soluble in water, producing liquids of high viscosity and are character­
ised by their high ester sulphate content. Because of their rheologica 
properties, the substances are frequently employed in the cosmetic and 
pharmaceutical industry’ to provide stability to suspensions, emulsions 
and foams. In the dairy industry, they are useful on account of their 
ability to alter the aggregation of casein in milk.
It is now being suggested that the carrageenan derived from a 
particular seaweed is a mixture of polysaccharides, the yield varying 
possibly, according to the species, the habitat, age and conditions 
during growth, the season in which it was harvested, and on the method 
of extraction.
From carrageenan solutions, two components are evident in the 
ultracentrifuge in all samples of high viscosity. Fractions corres­
ponding to these two components have been separated by a method based 
on/
2.
/on the sensitivity of carrageenan to potassium salts.
Potassium salts increase the viscosity of carrageenan solutions 
and enhance their gelling properties. \%ien potassium salts are added 
to aqueous carrageenan solutions, too dilute to gel, a fraction is 
precipitated which may he removed hy centrifugation. This fraction 
has been designated the kappa (k) fraction, while the unaffected com­
ponent remaining in solution has been called lambda (A) carrageenan.
2—iThese fractions differ in some chemical and physical properties 
such as potassium sensitivity, sulphate content, optical rotation, 
X-ray diffraction patterns, intrinsic viscosity and sedimentation 
rates. The chemical constitution of the carrageenans has been exten- 
sively investigated but has not yet been completely elucidated.
The first structural studies showed that galactose units are 
present, esterified with sulphuric acid at position 4 ? and combined in 
glycosidic linkages through position 3. Some branching through posi­
tion 6 was also shown to occurs  ^ Later, another sugar component was 
identified^^as 3 y6-anhydro-I)-galactose. The k and A^z^ctions were
separated and, from the results of further experiments, a provisional 
structure was assigned to the k form. It is thought to exist as 
an alternating chain of 1,3"-linkedyS -D-galactopyranosyl 4-sulphate 
units and 1,4-linked 3,6-anhydro-cc-D-galactopyranosyl units as shown 
below. CHgOH GHg
OH
0
OH
0
k - C A R M G E E M
The fraction was further separated into a main component and a
polysaccharide containing L-galactose units}^ A possible structure for
the main fraction has been suggested as below.
CH2OÏÏ GH2OSO3"
Ip } V ” A-o
OH O8O3
Thus, the major differences between the two forms are
1) The X-carrageenan contains l,4“linked-I)-galactopyranose units in 
place of the 3,6-anhydro-D-galactose which occurs in the k form, 
and
2) the k-carrageenan contains a higher proportion of 4-sulphated 
H-galactose units.
12Further studies have shown, hov/ever, that the sulphates galactose 
ratio for the k polysaccharide is >1 and the molecule may therefore be 
more highly sulphated than the above structure would indicate. It is 
suggested that a sulphate substituent in position 2 of the 3,6-anhydro- 
galactose unit may exist.
Also, by controlled treatment of A-carrageenan with alkali, a 
polysaccharide related to k carrageenan can be prepared. It has there­
fore been suggested^^that the main component of À -carrageenan could be 
a biological precursor of the k form and this could account for the 
different percentage yields obtained from batch to batch. Possibly 
several enzymes are present in the living seaweed, capable of metabo­
lising/
4.
/metabolising the polysaccharides in a manner analogous to that of the 
alkali.
An enzyme specific for the hydrolysis of k-carrageenan has been 
extracted^^ from a marine bacterium. Its optimal conditions for 
activity, as measured by the amount of reducing sugar produced, were 
found to be a temperature of 40^0 and a pH of 7;5, Structural and 
stereoisomeric differences in the molecules of the k and X forms pro­
bably account for its specificity.
Despite incomplete Icnov^ ledge of the structure of the carrageenans, 
the k and A forms can be readily distinguished by analysis. The X- 
fraction has a higher sulphate and galactose content. Also, the 3,6- 
anhydrogalactose moiety constitutes about 25^ of the k fraction while 
in the "pure" A carrageenan, it is virtually absent. The infrared 
absorption spectra of the two fractions differ substantially, due to 
the different positions of the sulphate groups and to differences in 
stereoscopic arrangements.
The sulphated polysaccharides, by virtue of their structure, 
demonstrate a reaction with the basic dye toluidine blue. The colour 
of the dye, in the presence of carrageenan, changes from its normal 
(orthochromatic) blue, through purple, to reddish-violet (metachromatic) 
shades. This phenomenon of metachromasia is not a specific reaction of 
the carrageenans but is well-recognised for many substances, including 
heparin, and synthetic sulphated polysaccharides. Investigation has 
shown that the intensity of metachromasia is directly related to the 
sulphur/
5c
/sulphur content of the molecule but unrelated to its degree of polymeri- 
15sation. Although the reaction is apparent with very small amounts of 
polysaccharide, the non-specificity of the possible reactants limit its 
usefulness as a conclusive diagnostic test for the presence of 
carrageenan.
Biological Properties of Carrageenans
Various biological properties of the carrageenans have been re­
ported. Turner and Magnusson have described experiments^^ using the 
k and A fractions of carrageenan, extracted from the red alga, Chondrus 
crispus, as précipitants of twooC-glycoproteins. These formed a 
lipoprotein-polysaccharide complex which could be dissociated by high 
concentrations of salts, and the two components were separated by 
centrifugation. This property could be an important factor concerned 
in the biological actions of the carrageenans.
When injected subcutaneously into rats, a local granulomatous
17lesion has been produced , This effect has also been observed in the 
guinea pig^^, described as a deposition of dense connective tissue, of 
the collagen nature, later to degenerate and be replaced by adipose 
tissue.
Following numerous reports dealing with the clearing and anti- 
arteriosclerotic activities of heparin and other sulphated polysacc­
harides, the effects of intravenous carrageenan on serum lipids and 
atherosclerosia in cholesterol-treated rabbits has been reported^^.
Serum lipids were suppressed in the carrageenan-treated animals and 
the/
/the atheromatous lesions were less severe. This antilipaemic action
20had "been previously observed by Houck et al, in dogs, using a number
of polysaccharides including extracts of carrageenan from six different
species of seaweeds.
The antipeptic activity of sulphated polysaccharides was first 
21 22reported in 1935?  ^ using mucoitinsulphuric acid and chondroitin
23
sulphuric acid. This work has been extended to include heparin and
24degraded carrageenan , Carrageenan will alno prevent the occurrence
25 26 24of experimental peptic ulcer and it has been suggested that the
protection afforded is due to increased mucosal protection. Other 
27work suggests the possibility of a humoral mechanism in the preven­
tion of gastric ulceration.
Carrageenans have also an anticoagulant action. In 1935»
28
Bergstrbm found that polysaccharides with sulphate groupings showed 
some anticoagulant activity while similar derivatives of mono- and 
di-saccharides were inactive, A large number of synthetic anticoagu­
lants have been prepared by sulphating polysaccharides such as chon­
droitin, cellulose, inulin, starch and dextran. These substances all 
had relatively low anticoagulant activity and at equivalent doses 
higher toxicity than heparin.
The anticoagulant activity of the polysaccharide laminarin was 
first described by Jaques and Charles in 1941^^» and this has since 
been followed up by work described in several papers by Hawkins, 
Laminarin is a polysaccharide extracted from brown seaweed. It has 
a/
7,
/a molecular weight of 4?00C"8,000, contains no sulphate in the natural 
state, but sulphated derivatives may be chemically prepared, O ’Heill 
has demonstrated that these derivatives exhibit anticoagulant activity 
in vitro^^. Four derivatives, extracted from Laminaria digitata and 
subsequently sulphated to different degrees, were tested for anti­
coagulant activity in vivo in rats and dogs^^, wit^ heparin as the 
standard for comparison. Anticoagulant activity was measured by the 
capillary tube method, the blood samples being taken at intervals after 
an intravenous injection of the polysaccharide. The results indicated 
that the activities of the preparations varied from 1/2-1/2O of the 
potency of heparin.
A more detailed study of the anticoagulant activity of one of these
32sulphated laminarin preparations was then undertaken and the authors 
concluded that it acted, like heparin, as an antithrombic agent. In
vitro tests indicated that it had 1/5 of the activity of heparin. The
tests chosen to determine clotting efficiency were the clotting time, 
as measured by the Lee and White method, reoalcification time, thrombin 
time and Quick’s one-stage prothrombin time. Following an intravenous 
injection, in the case of both laminarin sulphate and heparin, a peak 
maximum effect was observed half an hour after the injection.
These authors also reported that laminarin sulphate showed lipaemia- 
clearing activity in the dog and rat, similar to that demonstrated by 
heparin.
Hawkins has since extended his work^^ to a study of the carrageenan 
derived/
/derived from Chondrus crispus. The extract was separated into k and
. 2
X fractions according to the usual procedure hy potassium precipitation . 
In both antipeptic and antithrombic activity, the A fraction was found 
to be more active than either the k-fraction or the unfractionated 
extract. These tests were carried out in dogs, anticoagulant activity 
being indicated by a lengthening of the clotting time and thrombin time. 
In vitro tests, using human blood, showed that carrageenan'has anticoagu­
lant activity but is much less potent than is heparin. Again, an anti­
thrombic activity is suggested for the polysaccharide although tests 
indicating deficiencies in the early stages of blood coagulation were 
not carried out. It is suggested that anticoagulant activity of the 
carrageenan may be associated with sulphate content since the A-fraction 
has a higher sulphate content and also a greater anticoagulant activity 
than the k-form. This corroborates the observation of Anderson and
24
Watt that among degraded carrageenans, antipeptic activity is direct­
ly related to sulphate content,
95Consequently, in vitro tests using human blood were carried out 
using the fractionated and unfractionated carrageenan. The results 
were similar to those obtained with dogs, though quantitatively, lower 
activity was shown, the most active A fraction being l/l? as effective 
as heparin. It is pointed out that since interest is being shown in 
the carrageenans in the treatment of peptic ulcer, in which anticoagu­
lant action is contraindicated, the anticoagulant action of carrageenan, 
although/
9.
/although demonstrable only after intravenous administration, ought to 
be further examined.
Adams and Thorpe have also conducted experiments which demon­
strate the anticoagulant activity of laminarin sulphate. The poly­
saccharide v/as extracted from Laminaria cloustoni and four preparations 
sulphated to varying degrees, were tested. In rabbits, using the 
capillary tube method for assessing anticoagulant activity, laminarin 
sulphate showed 1/3 of the activity of heparin, a result which is in 
agreement with that of Hawkins using dogs, A slightly more prolonged 
effect was seen than with heparin and the anticoagulant action could 
be neutralised by protamine sulphate, a property exhibited also by 
heparin. These authors, however, report that the toxicity of the 
polysaccharides tested would preclude their clinical use.
Further anticoagulant studies on carrageenan were reported in 
201957 by Houck et al , Dogs were used as the experimental animal and 
six preparations of carrageenan were tested for anticoagulant activity 
as demonstrated by the whole blood coagulation time. The seaweed 
sources were Furcellaria festigiate, Eucheuma spinosum, Gigartina 
acicularis, G, pistillate, G, radula and Iridaea species, in each case 
the unfractionated extract being used. Only with one preparation,
G, acicularis, was marked activity observed. Contrary to the work of 
Hawkins et al., a peak anticoagulant effect was observed four hours 
after the intravenous injection compared with a half-hour peak as 
occurs with heparin. The effect of the carrageenan was still evident
24/
10.
/24 hours after the injection. Various toxic symptoms were observed, 
in particular kidney changes reminiscent of glomerulonephritis.
General conclusions reached from the work which has already 
been carried out are that many sulphated polysaccharides do show 
some . anticoagulant activity in experimental animals, both in vitro 
and in vivo, the most active ones reported being the extracts from 
Chondrus crispus, Gigartina acicularis and the sulphated extract 
from laminarin sulphate. They were all less potent than heparin.
The mode of action has been suggested to be an antithrombic one 
but insufficient investigatory tests have been undertaken to show 
this conclusively, especially those tests which whould demonstrate 
deficiencies in the earliest stages of coagulation. Most experimenters 
have used the whole blood coagulation test as an index of coagulation 
efficiency and while this does indicate interference in the clotting 
process, it is an entirely non-specific test, often being the resultant 
of interference with several clotting factors. Therefore a coagulation 
time within normal limits does not conclusively indicate that no effect 
has occurred.
The greatest disadvantage to the possible use of these sulphated
polysaccharides as . anticoagulant drugs would be their high toxicity
following intravenous administration*. . In chronic toxicity tests in
rabbits, loss of tone in ileum and colon has been observed,and
diarrhoea or defaecation occurred in many oases. The animals showed
lethargy after the injection^ Histologically, the most pronounced
changes occurred in the kidneys, where degenerative changes in the 
convoluted/
11.
/convoluted tubules were observed and occasionally, fibrin clots in the
glomerular capillaries. These effects were suggested^^ to be possibly
due to agglutination of the blood platelets and precipitation of
fibrinogen, effects which have already been reported of many synthetic
sulphated polysaccharides.
In acute toxicity tests, the guinea pig appeared to be most
sensitive to the substances, but unlike the toxic action of heparin, the
effects did not appear immediately after l/v injection but after a time
lapse of 1-2 hours. Pulmonary oedema, bouts of jactitating movements,
limpness and finally death were the symptoms described, in some animals
causing death within an hour of injection while in other animals, a day
or two elapsed before the effects became fatal. These symptoms have been
ISdescribed by Walton and Ricketts following the parenteral adminis-
-tration of sulphate esters of high molecular weight dextran, and are
described as "anaphylactoid" reaction. Superficially, this resembles 
anaphylaxis but differs in that -
1. it occurred in animals not previously exposed to dextran sulphate
2. it was not accompanied by severe respiratory embarrassment and 
there was no sign of bronchiolar constriction or pulmonary emphysema
3. the reaction could not be prevented or inhibited by large doses 
of antihistamine.
Present understanding of the properties and actions of the carra- 
geenans is confused because different authors have used the term 
"carrageenan" referring to total extracts in some cases, and fractionated 
extracts in others. The variety of sources of carrageenan has been 
extensive,/
12,
/extensive, and frequently, the biological effects have been observed 
in different species of animals. It is therefore difficult to draw 
direct comparisons of results from different investigations.
The present study has noted and compared the anticoagulant effects 
of extracts, both fractionated and degraded, from different seaweed 
sources, because these above discrepancies have become more clearly 
understood. As it is the anticoagulant properties of the carrageenans 
which have been studied, it is necessary to consider the present 
knowledge of blood coagulation,
BLOOD CQAGIJIATIQN 
The transformation of fluid blood to a solid clot of fibrin 
occurs so quickly and spontaneously that it is difficult to envisage 
more than a simple scheme of events to bring it about. During the 
last twenty years, however, many steps in the early stages of clotting 
have been clarified and the presence of several hitherto unknown 
factors demonstrated. It appears that blood contains within it, the 
many clotting factors necessary to initiate and bring about complete 
coagulation and, at the same time, contains factors which prevent 
intravascular clotting and dissolve fibrin after it has performed 
its function. Confusion has arisen, and still exists, in the 
terminology applied to the various factors by different investigators. 
Different terms are often used to denote the same entities and in some 
cases, it is not clear which really are different and which refer to 
one/
13
/one and the same factor. In 1947? Owren^^ introduced a Roman numeral 
for his newly introduced factor V and this convention for all the known 
clotting factors, was adopted by the International Nomenclature Com­
mittee. This system has been adhered to with the newly recognised 
factors but is still not adopted for the long established terms such 
as fibrinogin, prothrombin and calcium. A list of factors with 
their common synonyms is included.
FACTOR
I
II
III
IV 
V
VI
VII
Vlll
SYNONYMS
Fibrinogen
Prothrombin
Thromboplastin, Thrombokinase 
Calcium
Proaccelerin, Labile Factor 
Accelerator Globulin.
Accelerin
Proconvertin, Serum prothrombin 
conversion accelerator (SPCA) 
Stable factor, Autoprothrombin I 
Antihaemophilic factor (AHF), 
Antihaernophilic globulin (AIîG) , 
Platelet co-factor II, Auto­
prothrombin II, Antihaemophilic 
factor B.
IX /
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IX Plasma thromboplastin component
(PTC), Christmas factor,
Platelet co-factor II Autopro­
thrombin II, Antihaemophilic 
factor
X Stuart-Prower factor
XI Plasma thromboplastin antecedent
(PTA)
XII Hageman factor.
The first theory of blood coagulation, referred to as the classical 
theory, v/as postulated in I905 by Morawitz , as follows:-
TISSUE EXTRACT
PROTIlROmiN — ----------- >  THROmiN
CALCIUIÎ
THROMBIN
FIBRINOGEN ----  FIBRIN
From 1905 until 1940, a great deal of work was carried out, 
theories introduced, conflicting evidence produced, but with little 
real progress. The literature concerning work during this period is 
extensive and, while of interest in the historical and evolutionary 
sense, is not being reviewed in this account. Concern is now centred 
on present-day concepts of the blood coagulation process.
Most investigators are agreed upon the main reactions and essential 
substances for coagulation, but opinions vary as to the links in the 
chain of reactions and as to where each substance contributes its effect, 
Owren^^/
15
3 Q
/Owren has outlined his concept of blood clotting (see ovgr ) and 
has given an account of the experiments performed with evidence obtain­
ed in support of it, Quick^^ describes his concept of the coagulation 
process in four stages, similar to Ov/ren's theory except for the 
initial stages in which he describes a clotting factor erythrocytin, 
derived from the circulating erythrocytes on interaction with blood 
platelets,
r-Contact factor 
I (inactive) STEP 1
Factor IX 
(inactive)
Contact factor + Platelets 
(active)
Factor XII
Factor XI
STEP 2
Factor Vlll Factor IX
Thromboplastin
Prothrombinegen
Calcium + Factor V + Factor VII + Factor X + Prothrombin
STEP 3
Catafytic^ Reaction______ Thromfein
Removal
STEP 4
Adsorption  Fibrin
Blood Coagulation Theory Of Quick,
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charged 
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Blood Coagulation Tlieory Of Owren,
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The hypothesis suggested by Biggs and Maofarlane^^, very clearly 
demonstrates possible extrinsic and intrinsic prothrombin activator 
chains of reactions, Factor X is the focal point of the process, for 
both systems, and it is suggested that the active product formed on 
each route, which acts with factor X, could possibly be the same 
substance.
EXTRINSIC
TISSUE FACTOR
FACTOR ¥11 
CALCIUM
INTRINSIC
FACTOR Xll + FACTOR XI
PRECURSOR FACTOR IX
\v
CONTACT ACTIVATION PRODUCT 
CALCIUM
ACTIVE PRODUCT
ACTIVATED FACTOR IX + FACTOR Vlll
CALCIUM
FACTOR X + ACTIVE PRODUCT
^  PHOSPHOLIPID
ACTIVE FACTOR X -- ^
CALCIUlî
\k
ACTIVE PRODUCT + FACTOR V
CALCIUlJl
PROTHROMBIN
PROTHROMBIN
ACTIVATOR
CALCimd
r
THROMBIN
FIBRINOGEN 
— ^
\
FIB:.RIN
BLOOD COAGULATION THEORY OF BIGGS AND MACFARLANE
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Blood Cba^'Ulatioh Factors 
Briefly, we may consider the properties,important for the under­
standing of the clotting tests, of the various factors involved, as 
far as present knowledge allows.
Fibrin, This is an insoluble protein produced in the coagulation 
of blood, A network of protein strands of fibrin is laid down and 
in the interstices of this network, large amounts of liquid may be held, 
though easily extruded on slight tension or pressure. The fibrin clot 
has considerable strength and is strongly adhesive to surfaces such as 
body tissues or glass. Its molecular weight is probably similar to 
that of fibrinogen though it is thought to have a shorter molecular 
length.
Fibrinogen, Fibrinogen is a globulin, normally present in the 
circulating plasma from which it can be readily precipitated by salt 
solutions e,g, 0,25 saturated ammonium sulphate. Estimates of its 
molecular weight agree at about 340,000 , and its shape is considered
elongate and nodular. By the action of thrombin, fibrinogen is con­
verted quantitatively into fibrin.
Thrombin, Thrombin is a specific proteolytic enzyme, produced 
in the process of coagulation and which acts upon fibrinogen, probably 
disrupting the arginy1-glycine bonds in its molecule. These so-formed 
"fibrin monomers" polymerise, in a reaction which is independent of 
thrombin, to form the protein strands of fibrin polymer. Thrombin 
is/
19.
/is not normally present in plasma, but is formed from its ; precursor 
prothrombin.
Prothrombin, This is an oC-globulin with a molecular weight of
68,000 and an elongate shape. It is synthesised in the liver, in the 
presence of vitamin k , a vitamin important also in the synthesis of
A 2
factors VII and IX . It appears that in the conversion of prothrom­
bin to thrombin, the prothrombin molecule undergoes proteolysis, and 
derivatives, which show thrombic activity, have been isolated, of about 
half its molecular weight.
Prothrombin in plasma can be activated by the addition of tissue 
extract in the presence of factors V, VII, X and calcium. It may also 
be activated in the absence of tissue damage, by contact with a "foreign" 
surface, along with factors V, VIII, IX, X, platelets and calcium.
The former is called the extrinsic system of activation while the latter, 
the intrinsic system.
Extrinsic System of Prothrombin Activation. Tissue extracts, 
usually prepared from brain, lung or placenta, exhibit the property 
of accelerating blood coagulation and as this was originally thought 
to be the sole accelerating effect on the prothrombin-thrombin conver­
sion, in the presence of calcium, the term "thrombokinase", followed 
by thromboplastin, was applied to the active principle. Now, this 
term has been used both to denote the activity of tissue extract and 
of tissue extract in addition to various plasma factors. To avoid 
confusion/
20.
/confusion, Straub and Duckert^^ have suggested the use of the term 
extrinsic prothrombin activator for the prothrombin converting system 
derived from plasma and tissue factors.
The active constituent of brain extract is considered as being 
a lipo-protein of large molecular vjeight which can be centrifuged at
10,000 r.p.m. There appears to be an optimal concentration of tissue 
extract indicating the presence of an inhibitor which has been extracted 
from brain tissue. Tissue extract and calcium alone may convert pro­
thrombin to thrombin but the reaction is exceedingly slow in the absence 
of the factors V, VII and X.
Factor V is a constituent of the globulin fraction of blood plasma 
but has not yet been isolated or prepared in a pure form. It is un­
stable, deteriorating rapidly on storage, is destroyed by heating and 
is not adsorbed, like prothrombin, by inorganic précipitants. Factor 
V is present in plasma but is reduced or absent in normal serum, showing 
that it is consumed during the clotting process. It has been shown 
that human blood contains a lower level of factor V than the blood from 
other naimals"^^.
Factor VII is a/3 -globulin found in normal plasma and serum.
It is difficult to separate from prothrombin since in most fractiona­
tion processes, they are adsorbed or precipitated together, but a 
chromatographic method has been developed which effects a separation.
It acts, like factor V, as a prothrombin conversion accelerator, and 
is/
21,
/is present in man and other mammals to a similar extent.
Factor X has been recognised more recently since a patient
suffering from lack of factor VII could provide this factor and so re­
turn the blood picture of a patient suffering from lack of factor X to
normal. It has also been called the Stuart-Prower factor, named after 
the first patients to show its defect. It is ancC-globulin, present 
in both plasma and serum, is adsorbed by alumina and similar adsorbents, 
is destroyed by heating but is stable on storage. Its concentration 
is reduced by liver disease, by dicoumarol or by vitamin K deficiency.
Experimental evidence^^ has indicated that tissue extract reacts 
initially with factor VII and calcium, then factor X and calcium.
This resulting intermediate product could react with factor V to give 
a potent prothrombin activator.
TISSUE EXTRACT
\V
FACTOR Vll 
CALCIUM
ACTIVE PRODUCT + FACTOR X
I
ACTIVE FACTOR X 
FACTOR V
PROTHROMBIN
 —
CALCIUM
THROMBIN
V
+
PHOSPHOLIPID 
^ I CALCIUMi
ACTIVE PRODUCT
CALCIUM
PEOTmOMBIU ACTIVATOR
22,
Intrinsic System of Prothrombin Activation, It appears that 
normal plasma itself contains all the factors necessary to promote 
normal clotting without access to tissue extract from damaged cells,
A number of clotting factors appear to be necessary. Factors V and 
X take part in the activation of prothrombin in the intrinsic system 
while factor VII plays no part.
Factor VIII, or antihaemophilic globulin, is required for the 
normal clotting process and is the substance lacking in the blood of 
haemophilia patients. It is a/3-globulin, separates with the fibrino­
gen fraction on salt precipitation, and its activity is lost rapidly 
after withdrawal of blood and storage. Since it is present in plasma 
but not in serum, it must therefore be consumed during clotting.
Factor VIII has been shown to occur in the blood of the rabbit
Factor IX is also commonly referred to as Christmas factor, the 
name of the first patient recognised ss to be suffering from its defect. 
This haemorrhagic condition closely resembles haemophilia and it is 
only recently that the two have been differentiated. It is a/3- 
globulin, easily destroyed by heat but relatively stable on storage. 
Serum appears to contain more factor IX than plasma and this has led 
to the conclusion that it exists in plasma in an inactive form but is 
activated on contact with a foreign surface.
The platelets are thought to release, on contact with a foreign 
surface, a phospholipid or phospiiolipo-protein substance which takes 
part/
23
/part in the production of the prothrombin activator. Phospholipids
from sources other than platelets e.g. a chloroform extract of brain
tissue, can show similar activity and may be used as platelet substi-
47tute in the thromboplastin generation test , The actual active sub­
stance has not yet been identified from any source.
The hypothesis suggested for the intrinsic activator system by 
Biggs and Macfarlane is as follows, though experimental observations 
are more confusing than conclusive.
FACTOR Vlll + FACTOR IX 
I CALCIUM 
ACTIVATED FACTOR IX —
PRECURSOR OF FACTOR X
PHOSPHOLIPID
V
ACTIVE FACTOR X 
CALCIUÎI
FACTOR V ACTIVE PRODUCT
CALCIUM
\|/
IHTRIHSIG PROTHROMBIN
ACTIVATOR
24.
The activation of factor IX has been a subject of interest and 
conjecture in recent years, with the establishment of two new factors, 
factor XII (the Hageman factor) and factor XI (plasma thromboplastin 
antecedent). Patients suffering from a deficiency of these factors 
show abnormal blood reactions in vitro but show only slight or no 
haemostatic defect. In some way the factors influence the reaction 
of the plasma on a glass surface, so their activity is not well-marked 
if silicone-coated apparatus is used. Their mode of action is not 
clear but they are thought to act together forming a contact activation
product which is able to activate factor IX.
FACTOR Xll + FACTOR XI
FACTOR IX PRECURSOR ^
^   — ----- CONTACT ACTIVATION PRODUCT
FACTOR IX
They may be associated with either the /$ or Y -globulin fraction
of plasma proteins, are resistant to heat,but changes in clotting
efficiency occur on storage.
Calcium. In 1890, Arthus and Pages^^ established that calcium is
necessary for the formation of thrombin. Since the activity of calcium
is lost on the addition of oxalate or citrate, it was concluded that
ionised calcium was important for its accelerating action but in 1940,
49Quick suggested that bound, rather than ionised, calcium was required. 
By/
23.
/By adding sodium oxalate to blood, which would immediately remove ionic
calcium and inhibit clotting at once, a slow loss of coagulability is
observed. Quick believes that this slow action results from gradual
removal of bound calcium, possibly from a clotting factor,
50Quick has given evidence which suggests that calcium acts
stoichiometrically in the prothrombin-thrombin conversion. However,
51Lovelock and Porterfield suggest that calcium is used in the coagula­
tion process in the adsorbed state and that its chief function is to 
maintain the surface charge necessary for the interaction of various 
plasma colloids.
It is difficult to study the role of calcium in individual clotting 
reactions, since these cannot be carried out in pure solutions. The 
activation of factors XII and XI, followed by factors VII and IX can 
occur Vvdthout calcium, but are enhanced in its presence. The reaction 
between thrombin and fibrinogen can also occur in the absence of calcium 
but, while an. excess of calcium acts as an inhibitor, an optimal concen­
tration is an accelerator. It is probable that calcium is necessary 
for the activation of prothrombin in both the extrinsic and intrinsic 
activator systems. A complex involving calcium in addition to other 
factors necessary for the activation of factor IX has been suggested^^.
However, the precise role of calcium, although necessary for 
several stages, and acting as an accelerator in others, remains obscure.
This account relates the present state of knowledge regarding 
blood/
26.
/blood coagulation and includes hypotheses which may be outdated in a 
few years time. In anticoagulant studies, our conclusions of the 
possible mode of action of drugs are founded on the results of clotting 
efficiency tests based on the above theory. These tests may in the 
future be proved faulty but at the moment they provide us with the 
most satisfactory methods of investigation available,
HEPARIN
Chemical and General Properties 
In many anticoagulant studies, and in the consideration of 
possible new anticoagulants, heparin is taken as a quantitative and 
qualitative standard. It was the first therapeutically useful anti­
coagulant, is still used in most, acute thrombotic episodes, and is 
in fact regarded as a physiological, and therefore desirable anti­
coagulant substance. Heparin was discovered in I9I6 by McLean 
while he \ms extracting cephalin thromboplastin from tissues. The 
work was continued by Howell and Holt , who described the action of 
the extract in retarding blood coagulation and, because it was first 
extracted from liver, in which it occurs in fairly high concentration, 
it was named heparin. The substance was noon identified as a poly­
saccharide but despite much chemical investigation, its constitution 
is still not known. It is believed to be a mucoitin sulphuric acid, 
consisting of equal parts of hexuronic acid and sulphated glucosamine 
units. The sulphur content, of considerable significance for its 
activity,/
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/activity, is estimated, on average, to "be 11= The degree of
polymerisation and branching which exists is not known but the molecular 
weight has been estimated at approximately 20,000, A possible struc­
ture for the tetrasacoharide unit of heparin is shown below, though it 
is appreciated that heparin is probably not a single, well-defined 
chemical compound.
COOHCH20ÏÏ
OH0
OHM S O 3
TETRASACCHAEIDE W I T  OF HEPARIN 
The chemical structure may be compared with those of the 
carrageenans shown on pages 2 and 3.
Heparin is a strong, naturally-occurring acid, a principal 
characteristic of the molecule being its electronegative charge,
56
which is suggested as being a possible basis for its anticoagulant 
action. The negative charge may influence the proteins concerned 
in blood clotting and in some way prevent their participation in the 
clotting reactions.
Heparin, effective both in vitro and in vivo by intravenous 
route, is non-toxic in therapeutic doses. It exerts its peak effect 
after about I5 minutes, this short latent period being possibly re­
quired to allow full combination or complexing with the plasma 
proteins./
28.
/proteins.
Up to 50^ of an injected dose of heparin can be recovered in 
57the urine in various species. The remainder is believed to be
inactivated by the enzyme "heparinase", found in the liver, and by
its action the effectiveness of heparin passes within a few hours.
This enzymic activity appears to be non-specific and is possibly due
58to sulphatases known to be present in liver .
Correlation between chemical structure and biological activity 
of heparin has always been sought in an attempt to discover a synthetic 
substitute for clinical use because heparin is expensive to prepare, 
is difficult to purify in large quantity, must be given parenterally, 
has a short duration of action and is therefore not ideal for pro­
longed therapy. The importance of the sulphate groups was recognised
59when it was sho^ vn that anticoagulant activity appeared to rise with 
increase In sulphate content. There followed many reports^^'^^ of 
work on polysaccharides, sulphated to varying extents and with varying 
N-sulphates 0-sulphate ratios but a definite conclusion regarding the 
structures essential for the activity of heparin cannot yet be reached. 
The sulphamino group, unique in biological substances, electronegativity 
and suggestions such as 8-bridges, all appear to be involved. Further­
more, when heparins from different species are compared^^, the corres­
pondence between activity and sulphur content is less clear, due pro­
bably to variations in other molecular characteristics.
Mode of Anticoagulant Action./
29.
/Mode of Anticoagulant Action.
Although the antithrombic activity of heparin had been accepted 
for some time, increasing attention has more recently been focussed 
on the way in which it interferes with earlier stages of blood coagu­
lation, and the apparent inconsistencies in the literature regarding 
its action probably arise, at least in part, from the numerous vari­
ables, not always readily controlled, in experimental procedure. In 
addition to this, different concentrations of heparin are now believed 
to affect the various stages in the clotting sequence to predominantly 
different extents.
The idea that heparin might affect the early stages of clotting 
is not new and was introduced by Howell^^ in 191?9 his experiments 
suggesting that heparin acted as an antiprothrombin. However, Quick^^ 
supposed that heparin did not influence the action of thromboplastin 
and concluded that its activity could be wholly explained by an anti­
thrombic action, but in the following year, Brinkhous et al.^^ appeared 
to contradict this conclusion with their work which suggested antipro­
thrombin or antithromboplastin activity.
The precise action of heparin still remains obscure. It has been 
sho^m^^ that when purified thrombin was allowed to interact with pre­
pared fibrinogen, in the absence of plasma, no clotting occurred in the 
presence of heparin. It appears that heparin requires the presence of 
a co-factor, belonging to the albumin fraction of plasma, to exert its 
action. This co-factor, as yet, has escaped isolation and identifi­
cation./
30.
/identification. It has been suggested^^ that in vivo, heparin is
complexed with a lipo-protein and that during the extraction process,
the two components become separated, but heparin co-factor is not 
87believed to be identical to naturally-occurring plasma antithrombin. 
The anti-thrombin action of heparin is thought to be two-folds firstly 
to promote the adsorption of thrombin by fibrin, and secondly, to pre­
vent the enzymic action of thrombin oh fibrinogen. It appears that 
this antithrombic action is more pronounced with the larger doses of 
heparin than the smaller amounts, and is probably a relatively unim­
portant factor with small, or physiological concentrations of heparin. 
More important with smaller doses, are the effects of heparin on the 
earlier stages. Although the formation of thrombin is certainly de­
layed there is increasing evidence to suggest that several factors are 
affected in this conversion.
PROTHROMBIN -------  — ---— — — ^  THROMBIN
FACTOR V Ca++
FACTOR II 
FACTOR X
Tl-IROMBOPIASTIN ------  CONTACT
FACTOR VIII
FACTOR IX
66
Douglas has shovm that in the presence of heparin, factors V 
and Vll are not utilised and, coupled with defective consumption of 
prothrombin, he concluded interference in the protiirombin to thrombin 
conversion. O'Brien suggested^^ that heparin combines with, and 
therefore inactivates, factor IX, thereby delaying the formation of 
thromboplastin,/
31.
/thromboplastin. Normally, heparin is bound to plasma proteins and 
shows preferential affinity in the following orders- affinity for 
/3 lipoprotein < thrombin clotting system < factor IX < platelet pro­
tein ^  protamine sulphate. Thus, when bound with/^-lipoprotein, 
heparin is still available for delaying the thrombin clotting system. 
Bound to factor IX, it cannot influence the thrombin system and, on 
the addition of platelet protein, factor IX has been liberated^^.
The affinity of heparin for protamine sulphate is well-established, 
and this property is employed clinically for neutralising the action 
of heparin. The action is due to the presence of free basic groups 
in the protein molecule which combine with the acidic groups of heparin. 
It is appreciated, however, that the basic substance shows, in itself, 
anticoagulant activity and if present in excess of the amount required 
to neutralise heparin, there may follow an increase in coagulation 
time rather than the desired reduction,
McMillan and Brown^^ report that although normal serum does not 
contain factor VIII or factor V, they are present in the serum of 
patients treated with heparin, so indicating faulty thromboplastin 
generation. In the thromboplastin generation test, heparin delayed 
the formation, and decreased the amount, of thromboplastin produced. 
Large amounts of heparin actually destroyed preformed thromboplastin. 
Their results indicate that in small doses, the major effect of heparin 
is on the formation of thromboplastin and this would explain why the 
one-stage/
32.
/one-stage prothrombin test is either unaffected or very slightly length 
ened in the presence of heparin, the test itself providing a thrombo- 
plastic source.
It has now been shovm that heparin is physiologically present in 
the circulating plasma^^ and it probably exerts a prophylactic action 
to prevent spontaneous thrombosis by inhibiting thromboplastin genera­
tion,
AIMS OF THE PRESENT STUDY 
The present study was undertaken because of the difficulty in de­
ciding whether the various reports regarding the anticoagulant activity 
of carrageenans from red algae referred to the same or even comparable 
substances, A number of purified carrageenans were therefore prepared 
from different species of seaweeds from different habitats. It was 
considered of interest to establish whether or not these preparations 
showed anticoagulant activity of the same order as the few carrageenans 
already studied, and to investigate and compare the activities of k and 
A  fractions from samples obtained from different sources of Chondrus 
crispus (5 samples), Cigartina (2 species), in addition to the carrag­
eenan from Polyides rotundus, two degraded carrageenans, and one highly 
purified A carrageenan from Chondrus crispus.
As shown in TABLE A, the k and A fractions differ in sulphate,
3,6-anhydrogalactose, optical rotation and in inherent viscosity. The 
structure of pure X carrageenan is thought not to contain 3,6-anhydro­
galactose but fractionation of all seaweed extracts does not always 
give/
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/give a sharp separation into the k and A components, the A component 
often containing up to 10^ 3»6-anhydrogalactose. The anticoagulant 
activity and general toxicity, in rabbits, of the k and A fractions 
have been compared.
From these preliminary tests, four k and A fractions from 
different sources of C. crispus were selected for further investigation. 
The carrageenan from Polyides and the degraded carrageenan from Euoheume 
spinosum were also selected for further study. Effects on blood clot­
ting were studied in vivo, using rabbits as the experimental animal, in 
an attempt to gain some knowledge as to whether the various A's and k*s 
had similar activity and whether they interfered with the clotting 
process at the same stages. Tests were chosen which would demonstrate 
abnormalities both in the early stages of clotting and in the later 
stages. For comparison, the same tests were carried out using heparin 
as the anticoagulant, in doses which gave equivalent whole blood clot­
ting time results.
Some in vitro tests were carried out to investigate the effects 
of carrageenans on blood platelets and on fibrinogen since interaction 
with these seemed possible causes of the observed acute toxicity of 
many carrageenans.
For the main part of the work, two methods of approach were 
considered. Several tests of clotting function, and a larger 
number of substances could be examined using a relatively small 
number of animals; or a larger number of animals could have been/
35a-
/employed but fewer carrageenans would have been tested. The former 
approach was chosen, taking results from groups of four animals.
The consistency of these results have indicated a trend in the 
action of the various carrageenans and would allow subsequent 
construction of statistically designed experiments if quantitative 
differences were to be souMit.
E X P E R I M E N T A L
34-
PART 1.
PRBLII^gMRY EXPERII.m^TS TO PETERHgNE SUITABLE DOSAGE,
In ordor to determine a dosage level suitable for subsequent 
administration in coagulation studies, whole blood coagulation tests 
and toxicity observations were carried out in rabbits, using a number 
of carrageenans. The preparations investigated are listed in 
TABLE A.
Each substance was dissolved in 0-lM sodium chloride to give 
a solution of Many of the carrageenans were slowly soluble
and were therefore allowed to hydrate for up to 18 hours at 4^C after 
which dissolution had occurred or was effected rapidly with shaking 
at room temperature. Solutions were injected intravenously into 
rabbits, at the following dose levels (mg./kg) s 1,3,5 and 10.
The rabbits used were of mixed breed, male and female, and 
weighed between 1°Y5 and 3*75 kg. For each substance injected, two 
rabbits received the Img, dose, two rabbits the 3mg. dose, one rabbit 
the 5mg. dose and one rabbit the lOmg, dose.
The whole blood coagulation time was performed according to the
70method of Lee and hhite , The fur growing over the marginal vein of 
the ear was removed by means of a sharp scalpel blade, and slight 
vasodilatation produced by warming the carbon tetrachloride- 
cleaned ear with a lamp for a fevf minutes. A 3-5Run. incision was 
made in the vein with a new Hagedorn needle and the blood, freely- 
flowing,/
35,
/freely-flowing, was collected in tubes held under the ear. The first 
tube (imlc) was discarded to minimise tissue fluid contamination, and 
further 1ml. volumes were collected in each of four tubes, starting a 
stop-watch as the blood first flowed into each tube. The tubes were 
then placed in a water bath maintained at 37^G and each tube was tilted 
at half minute intervals until it could be completely inverted without 
dislodging the clot. The mean clotting time for the four tubes was 
recorded.
In the rabbit, the venous pressure in the ear is insufficient 
to make possible the convenient use of the syringe for repeated blood 
collection; and while blood could be obtained once in this way from 
the central artery, the resulting damage and general ischaeraia in the 
ear made subsequent sampling impracticable.
Initially, glass tubes 10 x 75nm« were coated with a jfo solution 
of silicone fluid MS 1107 in carbon tetrachloride, and baked at 150°0 
for one hour. This increased the normal coagulation time from an 
average of 5 minutes to 12-20 minutes and so small differences in 
coagulation time might then have become more obvious. It was found, 
however, that the range of times within the four tube samples was 
very much wider by this method and more consistent results were 
obtained with the uncoated glass tubes. The technique finally used 
was fully standardised and gave reproducible results, variation in 
times within the four tubes being in the range ip of the mean.
In/
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/in the preliminary tests, coagulation times were estimated, prior 
to the injection but due to the uniformity of the results and to avoid 
excessive blood loss with repeated bleedings, a normal coagulation time 
of 5-6 minutes was assumed; any rabbit having an abnormal coagulation 
time could be detected by failure of the clotting time to return to 
within normal limits at the end of the test. In results from 100 
rabbits, the mean coagulation time was found to be 5*4 minutes with a 
standard deviation of 0*5.
Preliminary experiments showed that maximum anticoagulant effect 
occurred 2 hours after injection (see TABLE 3) and that after 5 hours 
the coagulation time was returning to normal. For comparative purposes 
the results are tabulated as coagulation times, 2 hours after injection. 
(Results are in TABLE 1.)
At the higher dose levels, most of the substances were acutely 
toxic to the rabbits, causing death between 5 and 24 hours after the 
injection. TABLE 2 gives an indication of the corresponding doses 
of carrageenan which proved lethal to the rabbits within 24 hours.
Even with the lower doses, difficulty in obtaining blood was often 
experienced as the peripheral blood vessels, despite warming, remained 
flaccid with slow blood flow. After the injection, the rabbits often 
appeared listless and dyspnoeic with nasal discharge. The blood pres­
sure appeared low, satisfactory bleeding was difficult to obtain and 
in some cases, diarrhoea, and more often convulsions, preceded death. 
Post-mortem,/
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/post-mortem, the heart consistently appeared normal, hut the kidneys 
and lungs were frequently congested.
To ensure that the results were not influenced by the withdrawal 
and loss of blood, coagulation times were carried out on control 
rabbits, bleeding on four occasions at two-hourly intervals, Bo 
difficulty in obtaining blood was experienced and the coagulation 
times were consistent. It therefore appeared that the loss of tone 
and low blood pressure, so often causing difficulty in obtaining blood 
samples, was due to carrageenan.
38.
PART 2,
THE ANTICOAGULAirr AGTIQl OF VARIOUS OARRAGEMANS,
The following substances were studied?-
Code Bose
k” and A-carrageenan from Chondrus orispus GUS 3mg./kg. and 5mg./kg.
k- and A-carrageenan from Chondrus crispus Œ E  3mg./kg. and 5mg./kg
k~ and A-carrageenan from Chondrus crispus CSE 3mg./kg. and
k“ and A-carrageenan from Chondrus crispus CT 3mg./kg and 5mg,/kgc
carrageenan from Polyides rotundus 3nig./kgc
degraded carrageenan from Eucheuma spinesum 200mg,/kg.
Heparin Sodium 75i,u./kg, and 200i.u./kg
Because of its acute toxicity A-CHS at the 5n^ g./kg. dose level
had to be omitted from the study.
Four rabbits were used at each dose level of each substance.
Male.; albino, rabbits were chosen, weighing between 2‘0 kg. and 3'75kg.,
no rabbit being used on more than one occasion, Food was withheld for
18 hours prior to the tests being carried out, but water was allowed
ad lib.
Blood was collected from the marginal vein of the ear by the method 
previously described (Part 1.), 4 % 1ml. volumes being collected for the 
whole blood coagulation test. 2ml. of blood were added to a centrifuge 
tube containing 0*2ml. of 0°8^/ sodium chloride solution for the thrombin 
generation test, and 6*3ml. of blood added to another centrifuge tube 
containing/
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/containing O'Yml. of a 3*13"/ solution of trisodium citrate, mixed 
thoroughly to avoid clotting and the oitrated plasma was separated hy 
centrifuging for 10 minutes at 1400 rpm.
A total of eight tests of clotting function were carried out on
the blood withdrawn before administration of the carrageenan solution. 
The rabbit was then given on intravenous injection of'the carrageenan, 
the dose being calculated on the basis of body weight. The volume was 
made up to 8ml. with saline to avoid injecting very viscous solutions 
and to standardise the injection procedure.. Two hours after the in­
jection, the rabbit was bled from the marginal vein of the opposite ear. 
Again, the eight tests of clotting function were carried out. Thus, 
in each case, a comparison of the results of the tests before and after
the injection could be made directly, on the same rabbit.
Occasionally, due to the action of the carrageenan, blood flow in 
the ear was reduced and it was difficult to obtain the required volume 
of blood sufficiently free-flowing. In these cases, an injection of 
Hembutal Sod., 15mg./kg. body weight was given. This produced peri­
pheral vasodilatation and the blood flow became satisfactory for rapid 
collection. To ascertain whether the Nembutal itself v/ould interfere 
with the blood clotting tests, the tests were carried out on four 
rabbits prior to, and immediately following, an injection of 25mg./kg. 
body v/eight of Nembutal.
Results are shown in the appropriate tables.
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PREPARATION OF REAGEtTTS 
SOBIUIvl CITRATE SOLUTION.
A solution containing 3*13/ trisodium citrate was prepared in 
freshly distilled water, 1 os. bottles containing approximately 10ml. 
of this solution were sterilised by autoclaving, and one bottle v/as 
used on each day of the tests. Without sterilisation, the solution 
may rapidly become contaminated by moulds and bacterial growth.
CALCIUM CHLORIDE SOLUTION.
A 4/ solution of hydrous calcium chloride was prepared in freshly 
distilled water and standardised by titration with sodium ethylene 
diamine tetraacetate using solochrome black as indicator. This 
solution was diluted appropriately to give M/40 and M/20 solutions for 
use in the tests. Fresh solutions were prepared each week, to ensure 
consistent, optimal activity,
SODIUld CHLORIDE SOLUTION,
A 0,85/1 solution of sodium chloride was prepared. Where saline 
is referred to in this thesis, this solution was used,
O im ZN 'g VERONAL EDFEER.
1*175C of sodium diethylbarbiturate and l'46yC of sodium chloride 
were dissolved in a mixture of 157ml. distilled water and 43ml, of 
0,1N HCL. The pH of the final solution was checked or adjusted to
7*35.
THROMBIN SOLUTION,
Maw’s/
41.
/Maw's Thrombin Topical v/as used. It was supplied as a cream-
coloured freeze-dried preparation, each ampoule containing 50 units of
thrombin. This v/as dissolved in saline to give a solution of 20 units/
ml. for use in the tests. k fresh solution was prepared on alternate
days as, in solution, the clotting activity decreases rapidly.
BRAIN mROMBOPIAOTIN.
Fresh rabbit brain was chosen as the source of thromboplastin
since it is more easily freed from blood than is lung tissue, and, due
to this, the resulting preparation has been found to have a lower
72Factor Vll content. The method of extraction was developed from
73that described by Owren ,
Acetone-dried brain (thromboplastin source).
The brains were macerated with acetone in a glass mortar and 
maintained at a temperature of 4°C for 48 hours. During this time, the 
acetone was renewed on several eccasions, with mixing and grinding of 
the tissue before and after each change. The brain tissue, in coarse 
powder form with some fibrous tissue, was transferred to a MSE tissue 
homogeniser, with fresh acetone, and ground for 5 minutes. This finer 
powder was filtered through a suction filter and dried at 37°C for 
30 minutes.
A 3“4 weeks' supply of acetone-dried thromboplastin was prepared 
at a time, and stored at 4^0. It was found that, contrary to 
reports^^^^^, this thromboplastin preparation did not maintain its full 
potency/
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/potency for longer periods? even when stored in sealed ampoules.
Saline suspension of acetone-dried brain.
For use each day? 0'5G of the powder was weighed into a glass tube? 
10ml. of O'*85/ saline added, and the suspension incubated at 37°C for 
15 minutes, during which occasional mixing ensured dispersion of the 
powder in the saline. The supernatant which formed on standing was 
the thromboplastin preparation used in the tests.
Preliminary extraction experiments.
Tests were carried out using various methods of extraction.
Frozen brain, stored for one month at -20^0 before the extraction process 
was prepared as above but the resulting suspension was less satisfactory 
than that from fresh brain material? as indicated by activity measure­
ments c
In some cases, the dried material was mixed with saline and after 
thorough mixing? the suspension was stored frozen at -20^0 until re­
quired for use when it was reconstituted as before by incubating at 
37^8 for 15 minutes. No advantage over the standard method was gained 
by this method.
When the thromboplastin suspension was centrifuged and the super­
natant milky fluid removed for use? it was found to be slightly less 
active than the standard preparation which contained small particles 
in suspension,
Grinding in a small agate mortar produced a finely divided, even 
suspension/
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/suspension but its clotting activity varied throughout the day and 
results of the one-stage prothrombin test using it were inconsistent.
These methods were therefore discarded in favour of the one 
previously described which gave results satisfactory both in activity 
and in consistency throughout the day,
PUTELET SUBSTITUTE.
For use in the thromboplastin generation test.
This preparation was used as a substitute for platelet suspension
47and was prepared according to the method described by Bell and Alton
75and used by Hicks and Pitney . Acetone-dried, brain thromboplastin
powder, as prepared above, was tested for absence of cholesterol as
96judged by a negative Liebermann-Burchardt reaction , IG. of the 
powder was extracted at room temperature for 2 hours with 50ml chloro­
form. The mixture was filtered, the filtrate evaporated and the gummy 
residue, scraped from the evaporating dish, was homogenised (MSE tissue) 
in 50ml, of saline for 10 minutes to give the final suspension.
Dilutions of 1 in 50, 1 in 100 and 1 in 200 were made of this 
suspension in saline and tested by the screening test of Hicks and
75Pitney , to select the dilution which gave the shortest clotting times 
of substrate plasma. In this test, plasma was diluted with Owren's 
veronal buffer in the proportion of one part of plasma to nine parts 
of buffer, 0*5ml, of diluted plasma and 0*5^ 1, of the platelet 
substitute were mixed together in a test-tube in a water bath at 37^0, 
0*5 ml,/
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/0“5 ml, o|‘ M/40 calcium chloride solution at ^^s added rapidly
and a stop-watch started as the solutions mixed. At 1 minute inter­
vals, successive 0*1 ml. samples were removed from the mixture and 
added, together with 0^1 ml, of II/40 calcium chloride solution, into 
one of a series of tubes containing 0*1 ml, of substrate plasma pre^ 
viously placed in the water-bath. The clotting times of the substrate 
plasma were recorded. The results of the screening test are shown in 
TABLE 4 and from these, a dilution of 1 in 100 was selected for use 
in the thromboplastin generation test.
The concentrated suspension was kept frozen at -20 C and each day,
47it was thawed to be diluted for use. Bell and Alton report that the 
concentrated preparation retains its potency for 12 months, stored at 
-20 G and being repeatedly frozen and thawed. It was found, however, 
that after 3 months, the activity suddenly decreased and it was necess­
ary to prepare a further batch. ¥hen the second preparation was 
screened, similar clotting times to those of the first batch were ob­
tained with a 1 in 20 dilution, (see TABLE 4)? which was then used. 
FIBRINOGEN,
Fibrinogen was prepared according to the method described by 
Biggs and Macfarlane^^.
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Preparation of Alumina Suspension ,
100 ml. of ammonia solution (Sp. Gr. 0,88 diluted 1 in 2) was 
poured into 6OO ml. of water at 63^0 containing 22G, of ammonium 
sulphate/
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/sulphate and the temperature brought to 58^0. The mixture was stirred 
and poured, in one lot, into a solution of 76'7G. of ammonium alum at 
58^0 in 1 litre of distilled water. The mixture was stirred for 10 
minutes maintaining the temperature at 58°C and the precipitate was 
separated by centrifuging. The precipitate was washed five times 
with 1*5 litres of distilled water, the precipitate being separated by 
centrifuging on each occasion. To the first washing water, 0*22 ml, 
of Sp, Gr, 0*88 ammonia was added and to the second, 0*44 ml., The 
precipitate v/as suspended in water, making up a total volume of TOO 
mlso to give a gelatinous suspension which could be pipetted.
Preparation of Phosphate Buffer,
A 2M phosphate buffer at pH 6*6 was prepared by dissolving 8I7G, 
of anhydrous potassium dihydrogen phosphate in 1 litre of distilled 
water, to which had been added 750 ml, of 4^  ^potassium hydroxide.
After dissolving by heating, the volume was made up to 3 litres and 
the solution was filtered, M and M/4 solutions were prepared from this 
stock solution.
L no gen.
Fresh bovine blood was collected from the slaughter house in 
bottles containing 5/ potassium oxalate solution in the proportion one 
part of oxalate to nine parts of blood. The blood was centrifuged 
and the oxalated plasma separated.
To 1 litre of plasma, 50 ml. of aluminium hydroxide suspension 
was added and the mixture stirred at room temperature for 15 minutes. 
The/
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/The mixture was centrifuged and the sediment discarded. The super­
natant plasma was tested hy the one-stage prothrombin time method, 
and the clotting time was found to be greater than 1 minute, so en­
suring a low prothrombin content. The plasma was then cooled to 
12-14^0 and an equal volume of 2M. phosphate buffer at 2-4^0 was added. 
The mixture was allowed to stand for 15 minutes to allow the formation 
of a precipitate. The mixture v/as centrifuged for 10 minutes at 
2000 rpm. and the supernatant discarded. The precipitate was washed 
with 1 litre of M phosphate buffer, the precipitate recovered by centri­
fuging and then dissolved in 500 ml. of M/4 phosphate buffer. The 
volume was measured and the fibrinogen reprecipitated by adding an 
equal volume of 2M phosphate buffer. This precipitate was sedimented 
by centrifuging, and washed with 500 ml. of M phosphate buffer. Pre­
cipitation and washing were repeated once more and the final precipitate 
dissolved in 100 - 150 ml. of citrate saline (nine parts of saline and 
one part of 3*^b trisodium citrate). The solution was dialysed in the 
cold overnight against 5 litres of citrate saline, the dialysing fluid 
being stirred during this time. The product was centrifuged to remove 
any precipitate which may have formed and freeze dried. Drying was 
completed in a vacuum desiccator over phosphorus pentoxide.
For use in the tests, a solution containing Img./ml. of fibrinogen 
in saline was used. This concentration was found by considerable 
trial and error, using thrombin solutions, and in the prothrombin con­
sumption/
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/consumption test (see later), to give minimum clotting times and yet 
to produce a solid clot rather than wispy flakes of fibrin.
The dried fibrinogen product was kept at 4*^ 0 and maintained its 
potency for at least six weeks, a fresh solution being prepared each 
day. The first batch was used for eight weeks but between nine and 
twelve weeks, the activity gradually decreased and occasionally, when 
the solution was constituted for the day, a wispy precipitate appeared 
spontaneously two to three hours after preparation of the solution. 
Results during this period were discarded and the fibrinogen was con­
sequently prepared from fresh blood at intervals of six weeks.
HEPARIN
Heparin Sodium, Evans (15O units per mg.) was used to prepare a 
saline solution containing 100 units/ml.
PENTOBARBITONE.
Nembutal solution (Abbott) was used intravenously; 1 ml. of this 
solution contains 60 rag, of Pentobarbitone Sodium.
GLASSWARE.
Pyrex glass tubes, 10 x 75 mm. were used in all tests. Pyrex, 
graduated centrifuge tubes of 10 ml. capacity were used for the collec­
tion of blood. All glassware was cleaned by removal of the clots, 
scrubbed in warm water with a small quantity of detergent, thoroughly 
rinsed several times in warm water and finally in cold distilled water. 
The tubes were then dried in the hot air oven.
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PREPARATION OP GARRAGSmNS
Chondrus carrageenans.
Method of Extraction and Fractionation,
The extraction procedure was carried out by Dewar et al
2
12 using
a method modified from that described by Smith^. The principal 
stages in the process may be followed from the scheme outlined below.
Seaweed (dried and milled)
0,2^ 0 NaCl, pH 7? 20^0, extracted
centrifuged 
—  1
Supernatant
discarded
Residue
re-extracted with NaCl twice, 
at pO^G, pH 7 
Extracts
dialysed against 0*1 MaGl 
pH adjusted to 7? KGl added, 
centrifuged
k-polysaccharide gel
re-precipitated with 
KOI, centrifuged
NaGl added, 
dialysed against NaCl 
to r e m o v e t h e n  
against water to remove Gl' 
k-carrageenan
precipitated by ethanol 
dried
k-carrageenan
A -polysaccharide in solution
dialysed against NaCl 
then water, ethanol 
added
A-Earrageenan (solid)
49 0
Polyides rotundus.
The extraction process was similar to the above but no fractiona­
tion was possible since no gelling occurs on the addition of potassium 
chloride. The sodium salt of the carrageenan was prepared by dialysis 
against sodium chloride, followed by precipitation with ethanol.
The seaweed gave a low yield of a low viscosity carrageenan. 
Experimental evidence suggests that the carrageenan is similar to that
of a A-component from Chondrus crispus, with a high sulphate, and a
12low 3,6-anhydrogalactose content. It is believed that the 1,4-linked 
D-galactose 2,6-disulphate radicle present in A-carrageenan is not the 
major structural unit of Polyides carrageenan but may be replaced by
a 1,3-linked D-galactopyranose unit,
CH2OSO3 
' — 0
50/' \ r -  0
c r
OSO3
Carrageenan from Eucheuma spinosum,
12Eucheuma was extracted similarly to Chondrus but again, no 
fractionation was possible by potassium precipitation. V/hen potassium 
chloride was added, to a concentration of 0“25M, the solution thickened 
considerably but centrifugation produced no separation of the gel, even 
when the concentration of potassium chloride was increased. Experi­
mental evidence suggests that Eucheuma carrageenan contains no 
A-component/
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/A-component comparable to that of Chondrus, The polysaccharide is 
similar in structure to k-carrageenan but has a much higher sulphate 
content. This seaweed gave a high yield of the polysaccharide, of low 
viscosity.
For testing in experimental animals, a degraded product of the
12carrageenan was prepared , of low viscosity yet with a sulphate content 
similar to that of the undegraded substance.
Degraded A-carrageenan
Pure A-carrageenan and Polyides carrageenan are difficult to degrade 
satisfactorily by acid, presumably because of the absence of the acid 
labile 3,6-anhydro linlc in the polymer chain and the drastic conditions 
which would therefore be necessary would almost certainly remove a sig­
nificant proportion of the sulphate ester groupings.
12A method was developed for degrading A-type carrageenans satisfac­
torily by periodate oxidation, and was accomplished for theA -fraction 
of Co crispus (CNS). The viscosity was thus reduced from 21"? to 1*3
di/e.
Rees' pureX-carrageenan.
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Rees  ^ has extracted and purified A-carrageenan from Chondrus 
crispus obtained from the coast of Maine, USA. Its characteristics 
are shown in TABLE A.
It has been observed that the yield of carrageenan varied from 
different samples, the results being indicative of seasonal variation. 
With/
51.
/with C. crispus (CNS), lower carrageenan yields were obtained in the 
autumn than in the summer samples. Also, the k/A ratio varied widely 
in different samples and with the season of the year in which the sea­
weed was harvested. It is suggested that the k-polysaccharide accumu­
lates in the plant throughout the winter months.
The seaweeds investigated, their sources, time of harvesting, 
sulphate content, 3,6-anhydrogalactose content, galactose content, 
k/\ ratio, optical rotation and inherent viscosity are shown in TABLE A,
TESTS OP CLOTTING FUNCTION.
1“ Whole Blood Coagulation Time.
This test was carried out according to the method of Lee and
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White , already described. The results are tabulated in TABLE 5.
2. Thrombin Generation Test.
Macfarlane and Biggs^^, in 1953, described the method which was 
used. A row of test-tubes containing 0*4 ml. of fibrinogen solution 
was set up in the water bath. 2 ml. of blood was collected in a glass 
centrifuge tube to which had been added 0^2 ml. of 0=85/ saline solution 
mixed, and the tube held in the water bath at 37^0. At one minute 
intervals from collection of the blood, 0=1 ml. of the blood was re­
moved and added to a tube containing the fibrinogen solution, in each 
case the clotting times of the blood-fibrinogen mixtures being recorded. 
As sampling continued, a fibrin clot appeared in the blood and was held 
to/
% Viscosity is considered a relative indication of molecular v/eight 
of the carrageenan.
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/to one side of the centrifuge tube by a wooden swab stick while fluid 
samples continued to be taken. Sampling was continued until either 
the clotting time exceeded 3 minutes or until no blood remained, which­
ever occurred first. Prom the clotting times of each tube, the con­
centration of thrombin in the blood at the time of sampling was obtained 
from the thrombin-dilution curve (see below). By plotting thrombin 
concentration against time, a curve showing thrombin generation and 
destruction in the blood was constructed. The graphs for the blood 
of each rabbit, comparing normal with abnormal, are shown in APPENDIX I, 
Thrombin - Fibrinogen Dilution Curve,
Ma,w*s Thrombin Topical was diluted with saline to give solutions 
containing 20, 15, 10, 8, 5, 4s 3, 2, 1 and 0‘5 units of thrombin per 
ml, A series of test-tubes containing 0=4 ml. of fibrinogen solution 
were placed in the water-bath at 37^C and to these 0=1 ml. of the 
thrombin solutions were added, the clotting time in each case being 
recorded. For each thrombin solution prepared, duplicate additions 
to fibrinogen were made and an average clotting time obtained. The 
clotting times were plotted against thrombin concentration and a curve 
obtained, as shown in APPENDIX I. This curve was used in converting 
clotting times to thrombin units in the thrombin generation test and 
also in the two-stage prothrombin test. While these thrombin units 
have no absolute significance, they a.re useful in comparing amounts of 
thrombin formed in these two tests.
53.
3 = Throinbin Time
32
The method used was that described by Hawkins and Leonard 
0=2 ml. of oitrated plasma was mixed with 0=1 ml. of 0*85/ saline in 
a test-tube maintained at 37^8 in the water bath. 0*1 ml. of thrombin 
solution, containing 20 units/ml., was added and the tube tilted fre­
quently until a firm clot appeared. The time from the addition of 
the thrombin solution until the clot formed was recorded, and an average 
of three determinations calculated. A thrombin index has been calcula­
ted for the blood of each rabbit as follows:-
NORMAL CLOTTING TIME 
THROMBIN INDEX = _ _ _ _ _ _ _ _ _ _ _  X 100
ABNOÎÏÏÆàL CLOTTING TDÆE
and the results shown in TABLE 6.
4. Recalcification Time^^.
To a tube in the water bath at 37^C, 0=1 ml, of oitrated plasma 
and 0*1 ml, of saline were added and mixed. 0*1 ml, of M/40 calcium
chloride solution was added and a stop-watch started simultaneously.
The mixture was examined by gentle tilting at frequent intervals until 
a firm clot appeared. The time taken for coagulation to occur was 
recorded. This test was carried out in triplicate and the average 
clotting time calculated. For each rabbit, a recalcifioation index 
has been calculated as follows:-
NORÎ#L CLOTTING TIME 
RECALCIFICATION INDEX =      X 100
ABNORimL CLOTTING T i m
The results are shown in TABLE 7.
5• One " stage Prothrombin Test
54^
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0*1 ml. of thromboplastin suspension was added to a test-tube in 
the water bath at 37^0, containing 0=1 ml, of oitrated plasma and the 
solutions mixed, 0*1 ml, of i^ /40 calcium chloride solution was added 
and the stop-watch begun. The tube was tilted at frequent intervals 
until a firm clot appeared and the time recorded. The test was carried 
out in triplicate and an average result calculated. The results were 
expressed ass-
PR0THR031BIN INDEX = NORMAL CLOTTING T i m
  —   ----— ----  X 100
ABNORMAL CLOTTING TIME 
These are compared in TABLE 8,
6c T\to - stage Prothrombin Test,
Since it is now realised that the one - stage prothrombin test 
does not measure any one specific substance in blood but may be in­
fluenced by the absence of Factors V, Vll, and X as well as a very low 
prothrombin concentration, a more specific two - stage test has been 
described^^. The modification suggested by Biggs and Macfarlane^^ 
was adopted i.e, the thromboplastin suspension was diluted with saline 
approximately 1 in 20, so as to give a one - stage prothrombin time of 
between 25 and 30 seconds. The use of this diluted brain suspension 
slows the formation of thrombin and so makes the test technically 
simpler to carry out,
A/
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/a row of test-tubes containing 0=4 ml, of fibrinogen solution 
was set up in the water bath at 37^0. 0=4 &1. of oitrated plasma
was mixed with 0 = 4 ki1® of diluted brain suspension in another test- 
tube and 0=4 ml. of M/40 calcium chloride added, A stop-watch was 
started as the calcium solution was added, and at minute intervals 
0*1 ml, samples were removed from the incubation mixture and added to 
the fibrinogen tubes. The clotting time for each tube was recorded. 
During the first or second minute in a normal test, a clot appeared in 
the incubation mixture and tlais was removed by winding it on to a 
wooden swab stick and holding this to the side of the tube, so enabling 
further liquid samples to be obtained. Sampling was continued until 
the fibrinogen clotting time exceeded 3 minutes.
From the thrombin - fibrinogen dilution curve, the thrombin 
concentration at each minute, equivalent to the clotting times obtained, 
was read. From these figures, a curve of thrombin generation and ibr 
disappearance was drawn for the blood of each rabbit before and after 
the injection of carrageenan. The areas under the curves were computed 
with a planimeter and in each case, the area obtained for the abnormal 
was expressed as a percentage of the normal. (see TABLE 9),
7• Prothrombin Consumption Test.
The method used was the one described by Biggs and Macfarlane
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and discussed by Merskey , It measures the amount of prothrombin 
present in the original plasma and the amount remaining in the serum 
one/
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/one hour after the blood has clotted,
\fnen coagulation had occurred in the four clotting tubes for the 
Lee and Nhite method, the tubes were allowed to stand in the water 
bath at 37^8 for 50 minutes from the time of coagulation. The clots 
were then freed from the sides of the tubes with a wooden swab stick 
and centrifuged for two minutes at 14OO r.p.m. The serum was collected 
and at one hour after coagulation had occurred, the prothrombin consump­
tion test was carried out,
0*4 ml. of fibrinogen solution was added to four test-tubes in 
the water bath at 37'^ C, Another tube was placed in the water bath and 
ml, of the serum added to it. To this, 0*2 ml, of 0* 85^  sodium 
chloride solution and 0*2 ml, of M/20 calcium chloride solution was 
added immediately an<“ a stop-watch started. The contents of the tube 
were mixed and at 30 seconds from the addition of the calcium solution, 
0=1 ml, of the mixture was removed and added to one of the fibrinogen 
tubes. The clotting time of this mixture was recorded. At 60 seconds
from the calcium addition, a further 0=1 ml. of the mixture was trans­
ferred to a fibrinogen tube and again, the clotting time recorded.
The second part of the test was carried out in exactly the same 
way using 0=2 ml, of oitrated plasma in place of the serum. In this 
case, the mixture coagulated during the first period of 30 seconds, 
because the plasma contained fibrinogen so this clot had to be removed 
on a wooden swab stick before the 30 second sample was taken.
The/
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/The results show the minimum clotting time for the plasma ex­
pressed as a percentage of the minimum clotting time for the serum.
Minu clotting time of 
PKOTHROmill COIÏSTJIÆPTIOH INDEX » ^^asma_________  x 100
Min. clotting time of 
serum
The results of this test are shown in TABLE 10,
8. Thromboplastin Generation Test
The thromboplastin generation test described by Biggs and
Douglas^^ is sensitive in detecting abnormalities affecting the early
stages of blood coagulation. The simplified modification of this
75test by Hicks and Pitney was found to be useful for screening tests.
For this test, 12 rabbits were kept as controls to provide normal 
plasma. One was bled each day so that the blood loss over a period 
of time was not severe.
9 ml. of blood was collected from the control rabbit in 1=0 ml. 
of citrate solution, and centrifuged for 10 minutes at I4OO mp.m, A 
series of test - tubes each containing 0=1 ml. of this oitrated plasma 
was set up in the water - bath at 37°G,
The plasma to be tested was diluted one part of plasma to nine 
parts of veronal buffer, 0*5 ml. of the diluted plasma and 0=5 ml, 
of platelet substitute were mixed together in a test-tube in the water 
bath at 37^^* 8* 5 ml, of M/40 calcium chloride solution, previously
warmed/
58.
/warmed to 37^8, was added, mixed and a stop-watch started. At one 
minute intervals, 0“1 ml. samples of the mixture were removed and added, 
simultaneously with 0^1 ml. of H/40 calcium chloride solution, to the 
tubes containing 0*1 ml. of control plasma. The clotting times of the 
plasma were recorded in each case over a period of eight minutes. The 
clot which usually formed in the incubation mixture during the first two 
minutes of incubation, was removed by means of a wooden swab stick to 
allow further sampling. The results of clotting times of normal and 
abnormal blood are shown in TABLE 11,
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PART 3c
IF \aTRO PLATELET COURTS AED FIBRINOGEN PRECIPITATION TESTS.
In view of the acute toxicity exhibited by some of the carra- 
geenans on intravenous administration, some in vitro tests were carried 
out to examine possible causes of these toxic effects,
PLATELET COURTIER,
One Chondrus crispus carrageenan, GY, fractionated into its k- 
and X*components, Polyides and degraded Eucheuma carrageenans were 
selected for platelet count tests and their actions compared with those 
of heparin.
The method used for platelet counting was that described by 
op
Brecher and Cronkite'^ , modified by the use of citrate as anticoagulant 
and to diminish the agglutination of platelets inherent in the technique 
1ml, of blood was collected from the rabbit's ear into a tube contain­
ing O' 1 ml, of 3*5/^ sodium citrate solution and the contents mixed 
thoroughly to avoid coagulation. 0*9ml, of a carrageenan solution, 
of concentrations ranging from lf4 to 0*0Py,was added to the tube, 
mixed thoroughly and allowed to stand for 30 minutes, so allowing any 
reaction between carrageenan and blood constituents to proceed. This 
mixture was then drawn up to the 1 mark of a white cell diluting 
pipette and the pipette was filled to the 11 mark with a I/o solution 
of ammonium oxalate. The pipette was shaken for 3 minutes; there­
after, a Thoma counting chamber was filled, after having discarded the 
first/
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/first few drops of liquid from the pipette. The chamber was left 
for 20 minutes to allow complete haemolysis of the red corpuscles 
and to allow the formed elements remaining to settle. The free 
platelets in 5 groups of l6 small squares were then counted. Thus, 
if X is the total number of platelets counted, each square represents 
a volume of 1/4OOO cu,mm, and the blood is diluted, in all, 20 times, 
then the number of platelets in the blood sample is
X 4000 20
QQ X X = X X 1000/cu, mm, blood
Table 12 shows the platelet counts at each concentration of the 
five substances tested, with the counts obtained for controls which 
were always carried out concurrently, ho agglutination of the plate­
lets was evident in any of the controls examined, With k-OY, X-CY 
and Polyides carrageenan, agglutination of the platelets was obvious 
in every case, being most marked in the ones showing the lowest counts 
Degraded Eucheuma carrageenan showed some small agglutinates of plate­
lets but, as may be seen from the counts obtained, many free platelets 
remained. There was no noticeable platelet agglutination in any of 
the heparin tests as may also be observed from the counts tabulated. 
Approximate physiological concentration effects.
Attempting to correlate these in vitro tests with possible in 
vivo effects of the carrageenans, a calculation based on a 4mg,/kg, 
dose of Chondrus and Polyides carrageenan, a 200mg,/kg, dose of de­
graded/
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/degraded Eucheuma carrageenan and a dose of 75-200 l.U./kg, of heparin 
was made assuming the blood volume of a 2'5 kg. rabbit to be approxi­
mately 200 ml. If the carrageenan injected intravenously were diluted 
evenly in this blood volume, then additions, in vitro, of a 0*01^ solu­
tion represents the physiological concentration for k-CYX-CY, and for 
Polyides, 0=5^ is comparable for degraded Eucheuma and 0°00l/ and 
O'003/1 for heparin- Table 12A shows the platelet counts, at these 
concentrations, compared.
Platelet counts (in vivo)
Intravenous doses of k-CY,A-OY (5mg./kg, ) and degraded Eucheuma 
carrageenan 35ig-/kg. were administered to rabbits. Two hours after 
the injection, whole blood coagulation times and platelets cdtints were 
carried out- Table 12B compares the results which were obtained, with 
re1evant comment s-
REACTION OF CARBAGEElTAh V.TTH EIBPIhOGEh SOLUTIQhS-
1ml- of a 0*4/ solution of fibrinogen was added to 1ml- of carra­
geenan solutions, ranging in concentration from 0*625 mg-/ml. to 
0*005^:&'/ml. The concentration range for degraded Eucheuma carra­
geenan was five times as great, from 3"13 to 0«025 mg-/ml- The 
opacity of the mixture in each tube was then compared with that of a 
control containing 1ml, of fibrinogen solution and 1ml, of distilled 
water. The 0*4/ solution of fibrinogen was in itself, opalescent and 
three types of reaction were observedj 
1-/
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/lo the opalescence was removed by some carrageenan solutions 
2. no observable effect was detected 
3* a precipitate became obvious.
Table 13 indicates the reactions which occurred with each solution 
of carrageenan, and with heparin solutions.
D I S C U S S I O N
63-
PART 1.
PRELIMMÂRY EXPERIMENTS - DOSAGE AND TOXICITY,
The results show that the carrageenans examined interfere with 
the normal coagulation process of blood.
In Part 1 of the Experimental section, the k and A fractions 
extracted from seven sources of seaweed were compared by means of the 
whole blood coagulation time. In five of these pairs, the Xfraction 
consistently showed greater anticoagulant activity than the k-com~ 
ponent. With the other two seaweed sources, Chondrus crispus (CBC) 
and Gigartina radula, the actions of the k and X fractions could not 
be distinguished.
The X degraded fraction of Chondrus crispus (CNS) did not show 
activity which differed from the corresponding undegraded fraction but 
it was less toxic. This difference in toxicity may well be a reflec­
tion on their different molecular weights.
In most cases, very little, or no, anticoagulant activity was 
apparent at the lowest dose level (img./kg.), activity appearing at 
the 3ing,/kg, dose and increasing to lOmg./kg, when acute toxicity 
appeared. Thus, all the carrageenans showed anticoagulant activity 
but this was accompanied by acute toxicity, the two properties appear­
ing to run parallel. As may be seen from TABLE 2, in each case for 
which the X-fraction showed greater anticoagulant activity than its 
k counterpart, it also showed greater toxicity. The other two k and 
A pairs/
64'
//\ pairs shoved equivalent toxicity as well as anticoagulant activity. 
Degraded Eucheuma carrageenan produced no toxic symptoms at a dose 
level as high as IG./kg. possibly due to its much lower molecular 
weight p
A detailed study of these acute toxic effects,which appeared
35similar to the anaphylactoid reaction described by Walton and Ricketts 
should be carried out and would probably provide useful information 
regarding the actions of intravenous carrageenan.. On superficial 
examination, post-mortem observations have suggested kidney damage as 
a toxic effect but the possibility of emboli obstructing vital struc­
tures cannot be ignored. The carrageenans are generally of high 
molecular weight and so produce solutions of high viscosity. Degrad­
ed Eucheuma carrageenan, however, is non-toxic and gives a solution 
of relatively low viscosity.
Although the k and X fractions obviously differ in their anti­
coagulant and toxic actions, the X fractions from different sources 
vary only very slightly in their activity* In comparing the k frac­
tions from each seaweed source, there appears to be slight differences 
in their activities as indicated by the whole blood coagulation test, 
those from Chondrus crispus (CY) and from Gigartina radula showing 
greater activity than the others.
65.
PART 2.
BLOOD COAGULATION TESTS.
The results obtained in the experiments of Part 1 suggested that 
the carrageenans of the Gigartina species showed no additional features 
of special interest. It was therefore decided to confine the more 
detailed study to the Chondrus carrageenans, the degraded Eucheuma, 
and the Polyides, carrageenans. The latter tv/o are of special inter­
est because of their more marked anticoagulant activity, their lower 
molecular weights, high sulphate content and, in the case of Eucheuma, 
remarkably low toxicity.
The more detailed study with these selected carrageenans was 
undertaken with the object of localising their action in the coagulation 
process and of comparing their actions with those of heparin. Clotting 
tests designed to indicate deficiencies in both the early and later 
stages of coagulation were used,
1. Whole blood coagulation test. This is a useful but non-specific 
test, A prolonged coagulation time indicates interference in the 
coagulation system at one or more points but gives no indication of 
whether an effect is seen in the early or late stages of the process. 
However, a negative result i.e. where the coagulation time is still 
within normal limits, does not necessarily indicate no interference 
in the mechanism. The initial phases of coagulation are generally 
believed to occupy the greater part of the time, perhaps 3-4 minutes, 
and/
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/and if this phase is prolonged, the coagulation time may he increased 
substantially. The last phase occurs rapidly, perhaps in 15 seconds, 
and therefore even a ten-fold increase at this stage would be scarcely 
detectable in the whole process.
Confirming the results obtained in Part 1, in the four pairs of 
k and A carrageenans chosen, the X fraction was consistently more 
active, at both dose levels, than the corresponding k fraction, in 
prolonging coagulation time. The results also indicate a definite 
difference between the activities of the carrageenans from different 
habitats. CY and CNS showed greatest activity in both a k-comparison 
and A “Comparison. The fractions extracted from Civil showed least 
activity and its k fraction gave results which could be considered 
within normal limits. The lower dose of heparin (75 I.U,/kg.) showed 
activity within the range of activity of the Chondrus carrageenans. 
Heparin (2001.H./kg) was equivalent to Polyides carrageenan, at 
3mg./kg, , and degraded Eucheuma carrageenan, at 200mg,/kg* , showed 
only slightly less activity,
2. Thrombin generation tent. Measuring the amounts of thrombin 
formed at intervals of time after the collection of blood, this test 
is also non-specific and may indicate defects in the coagulation 
system at any stage. Nevertheless, it gives more information than 
the whole blood coagulation test, is more sensitive to minor defects, 
and gives a good picture of the general pattern of thrombin formation. 
There is no suitable numerical method of expressing the results of 
this/
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/this test hut they can be described graphically showing generation 
and disappearance of thrombin.
It is apparent from the graphs (Appendix l) that the Chondrus 
carrageenans, at 5nig./kg. , reduced and delayed the amount of thrombin 
formed. With CY, there was no apparent difference between the k and 
X fractions, both being effective, whereas in the other three pairs 
of carrageenans, the Xfraction exerted a more marked effect*
Of the four k fractions, k-CY and k-GNS were more active, but the 
four X fractions did not appear to differ significantly amongst them­
selves.
At the 3mg./kg. dose level, there was slight delay and decrease 
in the amount of thrombin formed in most cases. Differences between 
k and A fractions were less marked than at the higher dose level.
Polyides and degraded carrageenan showed a most marked delay in 
the generation of thrombin; and, of the thrombin formed, very little 
or none was detectable in the test.
The low dose of heparin gave a slight delay in the generation of 
thrombin, similar to the results of the Chondrus carrageenans. With 
the high dose, no thrombin was detected in the test, in three out of 
the four rabbits. In the fourth, there was a delayed and very small 
amount detected
3» Thrombin time. This test consists of adding standard amounts of 
thrombin solution to citrated plasma, thereby testing the efficiency of 
the/
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/the last stage in the coagulation process, the fihrinogen-fihrin 
reaction. A prolonged thrombin time could result from either a 
severely depleted free fibrinogen content of the blood, which could 
follow reaction of the carrageenan with fibrinogen, or to an-&btienzymi( 
action on the thrombin added in the test, by substrate competi­
tion.
At the 5ing‘/kg. dose, all the A's were considerably more active 
than the corresponding k fractions. Of the four k ’s, CY,GKS and CSE 
were similar in activity and more effective than (MI which was normal. 
In the case of the A fractions, CSE was most potent, followed by CY,
CNS and CMI.
At the lower dose,A -CY and A-CSE were more active than their 
corresponding k, while the k's and A ’s of CNS and CMI showed similar 
activities,
Polyides and degraded Eucheuma carrageenans, although equivalent 
to heparin (200 l.U./kg.) in the whole blood coagulation test, were 
very much less active than this dose of heparin in this test and even 
less effective than some of the A Chondrus carrageenans. The smaller . 
dose of heparin showed a marked action in this test while the higher 
dose had such a prolonged inhibitory action that clotting times could 
not be measured.
4* Recalcification time. Again, a non-specific test since calcium 
is probably involved in a great many of the stages in coagulation.
The/
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88
/The number of platelets present can affect the result of this test , 
hence centrifugation conditions are important and must he standard­
ised, If platelet clumping occurred then the clotting time in the 
test would be markedly prolonged, A prolonged recalcification time 
often indicates that the clotting process is interrupted at a stage 
prior to the conversion of prothrombin-thrombin.
In all cases, the recalcification time was prolonged. At the 
higher dose level of three carrageenans, recalcification time was 
prolonged more by the A ’s than by the k's. In the fourth, CY, the 
k, on average, ?/as slightly more active than the X , At 3mg,/kg, , 
similar results were obtained although the CMI pair did not influence 
the result of the test significantly, k-CSE appeared more active 
than the X-fraction. Generally, CY and CNS showed greatest activity, 
Polyides carrageenan prolonged the test to a degree equivalent 
to the low dose of heparin which was greater than any of the above 
effects. Degraded Eucheuma carrageenan prolonged the time to a 
considerably greater extent, equivalent to the effect of the large 
dose of heparin.
5. One-stage prothrombin test. In this test, thromboplastin and 
calcium are added in excess and, since it was formerly believed that 
clotting then depends only on prothrombin concentration, a prolonged 
clotting time would indicate lack or absence of prothrombin. However, 
it is now widely accepted that in the conversion of prothrombin to 
thrombin,/
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/thrombin, factors V, Vll, X and calcium are necessary in addition to 
prothrombin. The test is therefore not specific for prothrombin and 
is, in fact; very insensitive to hypoprothrombinaemia. Nevertheless, 
it remains a useful guide, is simple to carry out and provides infor­
mation on the efficiency of the reactions involving all these factors* 
With the Chondrus carrageenans, at both dose levels, the A-frac­
tion was consistently more effective in prolonging the clotting time 
than the corresponding k fraction. A definite effect was shown in 
this test in most cases although low doses of the least active k's 
gave only slight prolongation.
At both dose levels, differences were not marked among the 
k fractions, k-CSE and k-CNS showing slightly greater activity.
Little difference could be detected between the X fractions from 
different habitats, .\-CNS possibly showing greater potency.
Polyides carrageenan gave a protlirombin index of 58 and degraded 
Eucheuma carrageenan of 69. By this test therefore, these are more 
active than even the high dose of heparin which gave an average value 
of 86, equivalent to many of the k carrageenan samples. The lower 
dose of heparin (75 l.N./kg.) showed no effect whatever on this test.
6= Two-stage prothrombin tgg.t» This test provides a more specific 
estimate of the amount of prothrombin available for conversion to 
thrombin than the one-stage method. Thromboplastin and calcium are 
added to the plasma and at intervals of time following the addition 
of/
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/of oalcimn, samples are removed from the mixture and added to fibrin­
ogen. The clotting times of the fibrinogen solutions are noted and 
graphs can he constructed showing the formation of thrombin with time.
A peak, showing when the maximum quantity of thrombin is freely avail­
able is seen but very rapidly falls off because the thrombin is being 
neutralised by antithrombin. This neutralisation is probably occur­
ring from the start of the formation of thrombin and the peak thus 
represents the point at which the rate of formation of thrombin equals 
its neutralisation. The height of the peak may be used as a measure 
of prothrombin but this depends on the rate of the reactions which are 
proceeding and the efficiency of the thrombin neutralisation process.
It is now generally agreed that a better measure of total available 
prothrombin can be obtained by measurement of the area under the curve, 
the actual time and position of the peak bearing little weight in 
estimating total prothrombin concentration. The area under the abnor­
mal curve is expressed as a percentage of the normal area, for the 
results from each rabbit,
Differences between the results for corresponding X and k frac­
tions were in many cases not marked due to great variation within the 
results from the four rabbits. . At the lower dose level, the A fractio] 
of CNS and CMI indicated a more marked effect. In all cases, however 
the amount of prothrombin available for conversion to thrombin was 
lower after l/v injection of the carrageenan than before.
When/
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/WYien comparison is made between the k fractions, CY, CNS and 
CSE are of similar activity. CÎ£C showed lower activity. In general, 
OY and CNS show slightly greater activity amongst the A fractions.
Polyides carrageenan does not exert a marked action in this test 
being less active than the other carrageenans. Degraded Eucheuma 
does, however, markedly reduce the prothrombin available. Heparin, 
although interfering very slightly in the one-stage test, shows marked 
action presumably at least partly due to its antithrombic action.
The low dose of heparin is comparable with degraded Eucheuma carra­
geenan .
7« Prothrombin Consumption Test, The next two tests which were 
carried out indicate any abnormality occurring early in the clotting 
mechanism i.e. in the first stages, in the formation of thromboplastin.
When whole blood clots in a tube, practically all the prothrombin 
is converted to thrombin, the conversion depending upon the amount of 
thromboplastin formed. If there is any gross abnormality in thrombo­
plastin formation, then the conversion of prothrombin to thrombin is 
delayed or absent. The test is therefore an indirect determination 
of the amount of thromboplastin produced and the results should be in 
parallel with those of the thromboplastin generation test.
The test itself consists of comparing the prothrombin, remaining 
in serum one hour after coagulation has occurred, with that in plasma. 
The prothrombin consumption index, recorded as the plasma clotting 
time/
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/time as a percentage of serum clotting time is usually low, below 20/ 
due to the reduction of prothrombin in serum. Sometimes, however, the 
index of the blood tested after the administration of the carrageenan 
exceeded lOOfo, That is, the serum appeared to contain more prothom- 
bin than the plasma and this, one would think, is most unlikely. The 
reason for this finding cannot be explained but has already been noted 
in many cases^^^^^, in both thrombocytopenia and haemophilia* It
appears that whenever the platelets are removed, an index of>10C^ is 
obtained.
The results of the test show that in every case in which a carra­
geenan had been administered, there followed an increase in the index, 
so showing a less efficient consumption of prothrombin in the serum.
The degree of effectiveness was extremely variable in the four pairs 
and no general trend was obvious when the k and X fractions were com­
pared, the four k fraction, and the four X fractions*
With Polyides carrageenan, a marked increase was shown, giving an 
average index of about 150/, while Eucheuma showed slightly less activ­
ity.
Heparin (75I«U*/Kg') produced no effect whatever on the result of 
this test while the 200 I.U./Kg, dose of heparin increased the index 
markedly to an average of 335/
8. Thromboplastin Generation Test. The screening test as carried out 
75was found in a wide range of coagulation disorders to give as accur­
ate/
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/accurate and as sensitive results as the test of Biggs and A'lacfarlane^^ 
yet was very much simpler and quicker to perform. Its clinical limi­
tation is that it will not distinguish between haemophilia and Christmas 
disease, but is a non-specific test for disorders of thromboplastin 
generation. It was originally devised to study the intrinsic prothrom­
bin activator system.
The test consists of reoaloifying diluted plasma in the presence 
of a platelet substitute and the thromboplastin which is generated is 
tested by adding samples of this mixture along with excess calcium, to 
normal citrated plasma. If there is defective thromboplastin genera­
tion, then the amount of thrombin formed is low and coagulation times 
of the normal plasma will be abnormally prolonged. It therefore de­
termines whether a deficiency exists in the early stages of blood 
coagulation.
At both dose levels of the Chondrus carrageenans, the X fraction 
in each case was more active than the k fraction. In all cases, there 
was an increase in clotting times and delay in formation of thrombin, 
so indicating a slow formation of a small amount of thromboplastin. 
Between the k components from different sources, there was no 
detectable difference, all increasing the final time by a factor of 
between one and two.
Comparing the X fractions, the average increase over normal values 
lay between 4 and 6 times normal, CMI being less effective than the 
other/
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/other three.
Polyides carrageenan did not produce a marked change, but one 
similar to the k fractions above.
Degraded Eucheuma carrageenan was potent in its inhibitory 
thromboplastic activity, producing a seven-fold increase in the normal 
values, a greater'increase^ than any of.the above A f^^^ -^ct ions.
Heparin, at 75 l.U./kg. showed only slight activity in this test 
causing an increase in clotting time of twice the original time, an 
effect similar to that of the k carrageenan fractions. The higher 
heparin dose gave results comparable with those of degraded Eucheuma. 
Pentobarbitone. The results of the tests in control rabbits given
an injection of Nembutal are reported in the appropriate tables.
There was no effect in six of the tests. In the recalcification 
test, a slight increase in index was obtained and a slight reduction 
of prothrombin was indicated in the two-stage prothrombin test. These 
tests were carried out in rabbits given almost twice the intravenous 
dose of Nembutal required to produce vasodilatation and to aid 
rapid bleeding from the ear, in a few carrageenan-tested rabbits.
It is therefore assumed that in these cases, the injection of Nembutal
did not influence the results of the blood clotting tests in carra- 
geenan-treated rabbits.
76.
GENERAL DISCUSSION.
Anticoagulant Activity.
Previous reports have dealt with the anticoagulant properties
20of seaweeds: Houck et al* reported that one of their extracts,
of Gigartina aoioularis, showed marked a c t i v i t y  while five other 
seaweed extracts did not, but none was-- fractionated. It is there­
fore possible that further differentiation of the carrageenan ex­
tracts could have revealed activity which has currently been 
overlooked. Rees has suggested^^ that A-carrageenan may be a 
biological precursor of the k-fraction, and it is possible that a 
seaweed be harvested containing a high proportion of the relatively 
inactive k polysaccharide. Hawkins and Leonard,on the other 
hand, have used an extract fractionated into its k and X components 
and have shown X to be more active biologically. The results pre­
sented here confirm this finding and show the extent to which their 
conclusions can be carried to other carrageenans. The X  fractions 
studied had a consistently higher anticoagulant activity coupled with 
a consistently higher sulphate content than the corresponding k frac­
tions, but while activity appears to be correlated with sulphate 
content, highest sulphate content does not ensure highest activity, 
X-CY having a higher sulphate but lower activity t!ian Polyides carra­
geenan. This may, however, indicate an optimum sulphate content 
for activity, though undoubtedly other factors are significant.
The/
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/The k and X-carrageenans differ widely in their 3|6 anhydro- 
galaotose content hut no relationship between content of this grouping 
and lack of anticoagulant activity can be seen. Degraded Eucheuma 
carrageenan has still a high 3y6-anhydrogalactose content but retains 
anticoagulant activity, although not at a similar dose level. Degra­
dation yields a much smaller molecule, with toxicity so reduced that 
anticoagulant activity can be demonstrated with safe intravenous 
doses,
As with heparin, it is unlikely that any one property of the 
sulphated polysaccharide structure is wholly responsible for anticoa­
gulant activity but more likely, a combination of several factors 
confers optimal activity, A certain sulphate content is obviously 
important, and maximum activity is seen when this is between 30 and 
35/, but a high molecular weight undoubtedly confers acute toxicity. 
However, molecular weight is not alone responsible for toxicity since 
a degraded carrageenan differs markedly in toxicity from a degraded 
k“carrageenan, of similar sulphate and molecular weights. Molecular 
configuration is also of relevance and must be extremely specific 
for the polysaccharide molecules which are large yet similar to each 
other in many chemical respects.
Localisation of interference in blood coagulation.
Since all the tests show a positive result to some extent, indica­
ting some interference in most of the stages of coagulation, it appears 
that/
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/that carrageenan affects many clotting factors* Probably, the 
effect is most pronounced on the earliest stages of coagulation 
since the thrombin time, which measures interference with the 
fibrinogen-fibrin conversion, is affected only slightly, and certain­
ly to a very much smaller extent than it is with heparin. On the 
other hand, the thromboplastin generation test and prothrombin con­
sumption test are affected in all cases and these tests specifically 
indicate a slow and defective production of thromboplastin, (or pro­
thrombin activator). The mode of action of the various carrageenans 
appears to be similar since the same tests are affected though to 
varying degrees. Thus, they possibly act in qualitatively similar 
ways but differ from heparin since a peak effectiveness is reached
within half an hour after intravenous heparin but two hours is necess-
32ary to show peak effectiveness for the carrageenans. Hawkins 
reports a peak effect for laminarin sulphate in dogs after half an 
hour whereas Houck et al.^^ found maximum effect after 4 hours with 
carrageenan extracts, in dogs, and found that anticoagulant activity 
was still evident 24 hours after the injection, a finding which this 
work has confirmed. This latent period for effectiveness cannot 
be explained at the present time but may possibly be due to inter­
action of the carrageenan with plasma proteins e.g. fibrinogen, or 
by causing clumping of the platelets. It would be of interest to 
determine whether the administration of heparin and carrageenan 
together,/
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/together, would influence the action of the former or whether they 
would act independently to produce an additive effect. At the low 
dose of heparin, the results of the one-stage prothrombin test and of 
the prothrombin consumption test were unaffected while with equivalent 
doses of carrageenan, as measured by the whole blood coagulation time, 
these tests were affected, so indicating a difference in mode of action, 
With heparin, the thrombin time was most markedly prolonged, again a 
distinct difference in mode of action being suggested* Thus, the 
carrageenans have shown differences, both qualitative and quantitative 
as regards anticoagulant actions, from those of heparin. Some clearer 
understanding of these findings might be forthcoming from the use of 
antagonists such as protamine sulphate, or toluidine blue, in conjunc­
tion with the carrageenans. With heparin, the actions of these anta­
gonists are well-established.
Since many of the carrageenans are acutely toxic, it was initially 
thought that the demonstrated anticoagulant action might be due to a 
release of endogenous heparin in greater than normal physiological 
amounts, as is believed to occur in conditions of shock. However, the 
marked differences which have been pointed out above eliminate this 
explanation. It is possible, nevertheless, that the effects seen in 
tests using acutely toxic doses of carrageenan may be complex, being 
a combination of true carrageenan action and of heparin release.
Further work could be extended to in vitro testing, using rabbit 
blood/
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/blood followed by tests on human blood. Results from such experi­
ments would be interesting, especially on consideration of the lag 
phase necessary for optimal anticoagulant action in vivo. Using 
rabbit blood, results would be directly comparable with those already 
obtained in vivo. These in vitro results could then be compared with 
advantage to those on human blood.
Intravenous toxicity of carrageenans.
As already described in Experimental, Part 111, platelet counts 
and fibrinogen precipitation tests were carried out on the carrageenan 
solutions, in vitro, Walton^^ has reported that large molecular 
weight dextran sulphates, (i.e. above 40,000), formed complexes with 
fibrinogen which were insoluble and led to instability of the formed 
elements of the blood, causing platelets and white cells to agglutinate 
Lower molecular weight dextran sulphates formed soluble complexes and
9;
were not found to cause agglutination of the formed elements, Walton 
has also shown the presence of emboli in various organs of mice and 
rats given acutely toxic doses of high molecular weight dextran sul­
phate.
Work has therefore been initiated to determine in vitro effects 
of carrageenan on blood platelets and on fibrinogen both of which are 
concerned in blood coagulation* Results from preliminary experiments 
are interesting and suggest further, more complete, investigation.
The free platelet count was markedly reduced in the presence of Chon­
drus/
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/chondrus and Polyides carrageenan while with degraded Eucheuma and 
heparin, no effect was apparent. It is of interest that as the con­
centration . of carrageenan v/as reduced so was the platelet count and 
platelet clumping became much more obvious, k fuller investigation 
of this effect, which is presumed from these experiments to reach a 
maximum at around physiological levels, is indicated, and should in­
clude other Chondrus carrageenans. The in vivo tests, although few, 
showed a marked difference in effect between the k and A carrageenan. 
The k carrageenan had caused platelet agglutination which v/as evident 
on the haemocytometer but the X treated blood showed no agglutination 
although the number of free platelets was small. These findings 
suggest that toxicity may well be related to the formation of emboli 
or precipitates to which the platelets become attached, which are 
then deposited in pulmonary vessels or other vital structures causing 
respiratory erabagassment and rapid fatality. Although these effects 
might be related to toxicity, they may also be of importance as a 
factor in the anticoagulant action since a thrombocytopenia might re­
duce the thromboplastin readily available in vitro and so affect the 
clotting tests.
The results of the reactions of carrageenans with fibrinogen 
may be seen in TABLE 13. Instructive interpretation of these pre­
liminary tests is difficult at this stage since care has to be taken 
to avoid making erroneous assumptions, A calculation based on a 
carrageenan/
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/carrageenan dose being diluted in 200 mis. of rabbit blood, evenly, 
gives an indication of approximate in vivo concentrations of carra- 
geenans and the results at these show no positive precipitation with 
fibrinogen. However, it may well be the case that in vivo, precipi­
tation or complexing of carrageenan with fibrinogen or other plasma 
proteins occurs rapidly and before sufficient time has passed to en­
sure thorough admixture with the entire blood volume. Even if com­
plexing with fibrinogen does occur under these in vitro conditions, 
a reaction with other plasma proteins will most likely also occur 
in whole blood and possibly this non-specific protein reaction involves 
many of the blood clotting factors in plasma. The toxic effects 
apparent on intravenous administration of carrageenan could be due to 
insoluble protein-carrageenan complexing with adherence of the blood 
platelets so forming obstructive emboli which become attached to en­
dothelial surfaces and eventually block circulation in vital structures 
leading to rapid fatalities. This must form the basis for further 
investigation to establish whether or not these assumptions are borne 
out in vivo and complete histological examination of post-mortem 
tissues would provide useful information.
With the higher concentrations of carrageenan, a clearing of the 
opalescent fibrinogen solution occurred, indicating soluble complex 
formation. An interpretation of this reaction and of its possible 
importance depends upon the exact nature of the substances causing 
the opalescence. If traces of insoluble fibrin are being solubilised
w
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/by the carrageenan, this might be of obvious importance as a fibrino­
lytic effect. A much fuller investigation, however, is necessary.
Y/hile the carrageenans from Chondrus crispus already tested 
show anticoagulant activity, their clinical use would appear to be 
precluded on account of their general toxicity, and further blood 
clotting investigation would thus be of academic, though not of clini­
cal, value, Further investigation into the toxicity, mode of action 
and possible clinical use of carrageenan from P. rotundus and degraded 
E. spinosum is suggested as being worthwhile from both thG^adademic ,and 
possible clinical viewpoint. The greatest activity, as indicated 
by the whole blood coagulation time, was obtained with Polyides 
carrageenan which showed just less than 1/2 the activity of heparin, 
weight for weight. Degraded E, spinosum showed 1/15O the activity of 
heparin but these comparative values are only significant when con­
sidered in relation to their toxicity. The carrageenans from C. 
crispus showed an average activity of 1/6 that of heparin but were, 
at that dose level, extremely toxic.
Interest is focused on the carrageenans not only for their 
anticoagulant action, but on account of their antipeptic and anti-ulcei 
activity. Possible anticoagulant action which they exhibit might ther 
be of importance not as the direct clinical action but as an important 
side effect.
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TlïBlE
AVERAGE COAGULATION TBIBS ( IF MINS) 2 HOUES AFTER K/ INJECTION.
1 mffA^ 3 mff/kff
GARRAGEEKâN 
CHOÎTDRÜS CRISPUS 
k FRACiJÎÏOK
eus
A PRACTIOU 
GHONDRUS CRISPUS 
k PRACTIOU
X PRAGTION 
CHONURUS CRISPUS 
k PRACTIOU
A PRACTIOU 
CHOUURUS CRISPUS 
k PRACTION
X PRJ^GTIOU 
CHOUURUS CRISPUS 
k PRjICTIOU
A PRACTION 
GIGARTINA STELLATA 
k PRACTION
A PRACTION 
GIGARTINA RiiUUU 
k PRACTION
A PRACTION 
polyides ROTUNDUS
c m
CSE
CY
CBC
6
8
6
7
6
7
7 
9
6
6
5
6
8
8
5
6
12
7
10
6
10
9
10
8 
7
6
9
11
11
20
CHONDRUS CRISPUS CNS
( A  PRilCTION, DEGRiYDED) 7 9
PURE A -CARRAGEEITAN 6 6
DEGRADED EUCHEUMA CARRAGEENAN 10 mff/kff 50 b/?/kff
5 8
11
TOXIC
7
12
7
13
10
13
7
8
8
10
12
TOXIC
TOXIC
8
10
l_QQ_mg/k.g
19
12
12
15
13
20
TOXIC
TOXIC
8
9
9
12
TOXIC
10
26
200 mff/kjj?
15
87
TABLE 2
CjVREAGEENM
SMALLEST BOSE PROVING FATAL 
WITHIN 24  HOURS (m g /K g )
k-PRACTION
( X, -F A C T IO N , DBGRABEB)
PURE X  -CARRAGEENAN 
POLYIDES ROTUNDUS 
DEGRADED EUCHEUWi C/iSR^iGEEBAK
A -P R jICTION
CHONDRUS CRISPUS CNS 5 3
tt 11 GMI > 1 0 3
ti II CSE 5 1
n 11 CY 3 1
(t 11 CBC 3 3
GIGARTINA RilDULA 1 3
It STELLATA m 50 20
CHONDRUS CRISPUS CNS 1 0
5
5
>1000
88
TABLE 3
lîAXIIvîOM AJÎTIGOAGULMT ACTION
CARRAGEENAN 
CHONDRUS CRISPUS
DOSE
mg/kg
VUÎOLE BL 
TI
0-5 HOUR
OOD COAGULAI 
ME AFTER ] 
2 HOURS
RON TIME (MINS) 
EJECTION
5 HOURS
k- CNS 5 6 10 TOXIC
k- CNS 10 7 12 TOXIC
X - CNS 3 5 13  ^ !
X- CNS 3 5 11 TOXIC
X- CNS 1 5 7 TOXIC
k- CMI 1 5 13 TOXIC
k- CMI 3 6 15 12
k- c m 5 6 21 19
X- CMI 1 6 11 7
X- CMI 3 7 13 TOXIC
X- CY 1 6 13 10
X- CY 2 7 13 TOXIC
k- CSE 2 5 8 6
T/xBLE 4
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SCREENING TEST FOR PLATELET SUBSTITUTE SUSPENSION
DILUTION
CLOTTING 
TIMES 
(IN SECS)
1,
2.
3.
4.
5.
6.
7.
8.
1 in 50
26 
12 
6 • 5 
7*4 
6*0 
6*0 
5*8 
7*0
1 in 100
15 
6*4 
6*0 
5*6 
5*4 
5 " 6 
6=0 
5-8
1 200
70 
22 
14
14
13
15
14 
14
SECOND PREPARATION
MINIMOTÆ
CLOTTING
TUffiS
(in secs)
1 in-. 100
11
1 in 50 1 in 20
90
TABLE 5 
raOLE BLOOD COAGULATION TEST
COAGULATION T i m  (mNS.)
A " EVICTIONDOSE CARRAGEENAN k- FRACTION
2 HOURS AFTER 
INJECTION
2 HOURS ilFTER 
INJECTIONINITIAL
CHONDRUS
CRISPUS GY 11
11 II
CHONDRUS
CRISPUS CMI
10
CHONDRUS
CRISPUS CSE
CHONDRUS
CRISPUS CNS
TOXIC TOXIC
AVERAGE
91
TABLE g (CONTB.) 
iïHOLE, BLOOD GOAGÜLATION TEST
COAGULATION TIME (MINS.)
DOSE CARRAGEENAN k- FRACTION K _ FRACTION
INITIAL 2 HOURS AFTER INITIAL 2 HOURS AFTERINJECTION INJECTION
3 mg/kg. CEOmRDS
CRISPUS CY 5 8 5
5 3i Ai
5 6i 3 II
5 3 Ai 9i
AmRAGE 5 6 3 10
3 mg/kg. CHONDRUS
CRISPUS c m 4 3 3i 8
4 Ai 3 8
5 3i 6 10
5 3i 3 10
AVERiiGE Ai: 3 3i 9
3 mg/kg. CHONDRUS
CRISPUS CSE 5 3i 3 li
Ai 8
5 6 3 8
7i 3 6
AVER/iGE 6è 3 li
3 mg/kg. CHONDRUS
CRISPUS CNS 5* 8i Ai 14
Ai 8 A 13
3i 9i 3 “
5 loi Ai 12
AVERAGE 5 9 Ai 13
-------  ■ — — — ■:(
TABLE 5 (Contd.)
92,
COAGULATION TBIE (MIN8.
2 HOURS AFTER 
INITIAL INJECTION
COAGULATION T i m  (MINS.)
2 HOURS AFTER 
INITIAL INJECTION
P. ROTÜÎTDÏÏS 4 28 DEGRADED 5& 9
3 mgo/kg. 3 I7u EUCHEUm 4t 21
3 19 CARRAGEENAN 6 13
4i 14 200 mgc/kg, 5& 25
AVERAGE 3-i- I9i 5i 17
0*5 ho ur after
INJECTION
0'5 HOUR AFTER 
INJECTION
HEPARIN 4i li HEPARIN 4 15t
75 i.n/kg. 4è 8| 200 I.U/kg. 5| 20
• 5 7 5 30
Ai 9 4& 16
AVERAGE Ai 8 5 20
IMMEDIATELY 
AFTER INJECTION
NEMBUTAL
(control) 5i 5
25mgc/kg, Ai
6
5t
Ai
5
jlVERAGE 5& 5i
TABLE 6
93.
THROiÆBIM TIME 
CE05DRUS CASRÂGEEtîAIIS. THK6}4BIR IKDEX,
DOSE CODE k X DOSE CODE k X
5mg,/kg. CY 83"0 61*0 5ing./kgc CMI 110.0 68.1
90» 7 64 * 0 90*5 63*0
86'5 53*8 99*0 71*0
71-8 94*1 108*5 66*7
AVERAGE 83*0 68*2 AVERAGE 102*0 67*2
5mgc/kgo CSE 77*8 46*0 5mg./kg. CNS 82*4 74-1
82-4 51*2 65*9 -
80»? 60*0 87*2 -
107.0 6l-1 82.6 —
AVERAGE 87*0 54-6 AVERAGE 84° 5 -
3mg./kg, CY 92-4 70*4 3mg„/kgo CMI 102*6 97*9
69*5 82*0 97-3 90*7
100*0 80*9 92*7 97'1
101*3 70*8 93'5 90*7
AVERAGE 90.8 76.0 AVERAGE 96*5 94*1
3mg./kg* CSE 84-2 71*4 Smg./kg CNS 86'9 72*9
‘ 72*6 79-4 87-5 92*9
90*7 80.9 82.2 91*2
79*6 65" 9 84*4 89*0
AVERAGE 81-8 74*4 AVER/iGE 85*3 86*5
TABLE 6 (Contd.)
94
THR0I4BIN INDE& THROMBIN. INDEX
P. ROTUITDUS 65 * 9 DEGRADED EÏÏCHEIDIÂ 57*3
3mg./kg. 58*8 200 mg,/kg. 58*9
66 * 7 48*7
94“ 8 66" 7
ATIRAGE 71*5 AVERAGE 59-9
HEPARIN 7*2 HSP7JRIN <. 0.59
75 i.u/kg. 2.7 200 l.u/kg. - 0'55
13-3 -0.55
8*6 <cO*55
AVERAGE 8'0 AVERAGE <0*55
. WBIJTAL 118*7
(Control) 95*4
25 mg./kg. 108*3
101*4
AIDERA GB 105*9
TABLE 7 
RECALCIEICATION TIME 
CKOHBRUS CARRAGEENANS - RECALCIEICATION INDEX
95
DOSE CODE
— - ----------
k A DOSE CODE k X
5nig./kg CY 46 • 0 81-0 5mg,/kg. mi 81*4 32*2
69.3 48*3 85*3 69 ° 9
106.7 89.4 62*3 39-3
58*9 :LIO'O 109*3 61 “4
ATERAGE 70*0 82 " 8 AVERAGE 84 - 6 50*7
5mg,/kg CSE 80 • 8 38.3 5mg./kg. CNS 73*0 15-7
57-1 56*0 36-8 "
42*3 61*6 48*4 -
100-0 47-1 116*9 -
AVERAGE 70*0 50*7 68° 8 -
3mg,/kg CY 51-6 44-4 3mg./kg. CMI 114*8 41*3
69 • 6 42.2 74-5 54*7
28-5 70-2 117-9 49*0
51*4 61,9 93*5 66.7
AmRiVGE 50*3 54“ 6 AVERAGE 100*2 52*9
3mg./kgr CSE 47 “1 58 "4 3mg./kg. CNS 59-1 45-5
82.7 47-2 71*2 32*5
96*9 71-5 86*8 81*5
81*6 56 “ 9 59-0 53-2
AVERAGE 77*1 58-5 AVERAGE 69*0 53-2
q6.
REOALGIFICATIOR
INDEX
ÎISOALCIPICATION.
INDEX
Po ROTUNDUS 
3mg./kg
36*7
23*1
45-5
58*5
J3EGRADSD EUCHEÜÎ.ÏA 
200mg,/kg
22*4 
19*1 
20 " 9 
20-3
AVERAGE 40*9 AVERAGE 20-7
HEPARIN 21*3 HEPARIN 20.6
75 i cu/kg. 36*7 200 i,n/kg. 42-0
56*8 18*7
49-0 18*7
AVERAGE 40.9 AVERAGE 25*0
NEMBUTAL 112*6
(Control) 111-7
127-0
122-2
AVERAGE 118*4
97.
TABLE 8 
ONE-STAGE PROTHROIABIN TEST
PROTHROMBIN
INDEX
PROTHROMBIN
INDEX
DOSE CODE k A
66*7
57‘6
57-8
51.2
DOSE CODE k X
5mg./kg CY 97° 2 
'69*0 
71*8 
75*2
5mg./kg, m i 98.0
76*6
98*4
95*7
74*2 
66-1 
50.3 
62.9
AVERAGE 78-3 58.3 average 92.2 63.4
5mg,/kg. CSE 92.6 78.0 5mg./kg CNS 81.7 73*1
64*2 64.9 74*1 -
73-4 56.6 94'4 -
84-5 48-0 85 4 -
AVERAGE 78*7 61*9 average 83*9 -
Smg./kgc CY 85-3 63-8 3mg./kgo CMI 93-7 58*2
92-3 78.7 100.9 73.9
111.I 53.4 76.2 78.5
90-3 80*9 75.4 68-3
AVERAGE 94*7 69-2 AVERAGE 86.5 69-7
3mg./kg« CSE 74*6 64-7 3mg,/kg, CNS 83*8 45*2
82*4 71*0 69° 9 54-0
84 - 8 80*8 95-1 47° 5
69-3 83° 1 74-5 50*5
AVERAGE 77-8 74.9 AVERAGE f80*8 49-2
98
TABLE 8 (Contd.) 
PROTBEOmm INDEX. PROTIIROÎSIÎÎ INDEX..
P. ROTUNDUS 50‘6 DEGRADED EUCHEUMA 58-1
3 ing,/kg. 57-7 200 mg/kg. 52*6 1
63*4 84 * 6
60 * 8 80-6
AVEMGE 58-1 AVERAGE 68*9
HEPARIN, 94*8 HEPARIN 85*4
75 i.n/kg. 100.0 200 i «u/kg. 98.6
111-4 78-1
95-5 81-1
AVERAGE 100-4 AVERAGE 85*8
NEMBUTAL 100*8
(Control) 129-1
25mg./kg, 99-3
95*5
AVERAGE 106.1
TABLE 9 
T.IO-STAGE PROTHROÎ/IBIN TEST
99
DOSE CODE
RATIO 01 
k
' AREAS (%)
A DOSE GODE
RATIO OP 
k
AREAS (/e)
X
5mg./kg. CI 70*6 38-3 5mg./kg« CMI 61*0 64:5
39*0 36-9 93*0 66-7
34*7 46-7 42-1 88-9
74-1 28-6 88-9 51-9
ATERâ CtE 54*6 38*1 AVICRAGE 71-3 68*0
5mg./kg. CSE 93'9 57-1 5mg,/kg. CNS 64-5 61 *6
66 *7 85*7 64 “0
58*3 41*0 70-8 -
45*0 44-4 52-6 -
AVERAGE 66:0 57-1 AVERAGE 63-0 *-
3mgo/kg\ CY 66*7 63-3 3mgc/kg. c m 45 “7 66 *7
51 “9 56-0 107-4 56*2
68 * 4 33-3 93*0 33-3
56*9 48-7 80*0 68 * 8
AVER/iGE 61*0 50*3 AmRJlGE 81* 5 56-3 '
3îng./kg. CSE 42*6 61-3 3mg,/kg. CNS 50-0 30*0
73-3 48-3 63° 2 32-4
47-2 54-5 46* 6 ■ 31-9
71-4 70-0 64*3 50-0
ATEiUGE 58*6 58 * 6 AVER/IGE 56*0 36-1 1
100
TlÆliE 9 (Contd.') 
TWO-STAGS PEÛTHRQMBIH TEST
m m o  OE AREAS ifo) RATIO OF AREAS (fo)
P. ROTUNDUS 29*4 DE(^)ADED ElTCÎIEÜIyUV. 50-0
3mg,/kg. 31-6 200mgo/kg. 9*1
35-0 33*3
77-3 21-4
AVERAGE 43-3 AmRilGE 17-2
HEPARIN. 10-7 HEPARIN 23*5
75 i.u./kg. 18*8 200 i.u./kgo 8,3
31*8 0.0
35*4 2-8
AVERAGE 24.2 AVERAGE 8-7
îWmUTAL 120.0
(Control) 55 “6
25mg./kg. 78-0
80-0
AVERAGE 83*4
101
TABLE 10.
PBOTHBOmiN GONSmiPTION TEST
PROTHROmiB CONSmCPTION INDEX
DOSE CODE - CiVHRiiGSSNANk" CARRAGEENAN
2 HOURS AFTER 
INJECTION
2 HOURS AFTER 
INJECTIONINITIAL
CY
31*1 42-411
CMI 11-9
17-0
30.3
16,0 10
18.8
CSE
CNS 30-0
26.3
67-7
61.5
20.0
11
46 * 4
102
TABLE 10. (Contd.)
PROTHROMBIN OONSmiPTION INDEX
DOSE CODE k- CARRAGEENAN A - CiNUR/iGEENAN
INITIAL
2 HOURS l'iETER 
INJECTION INITIAL
2 HOURS AFTER 
INJECTION
Smg./kg. CY 3-9 31-3 6*3 13*8
7*0 57*1 7*3 95*7
30-0 22-1 5.5 38*2
1-7 10*6 2*6 50*0
A^ TEETiOE 10-7 30*4 5*4 49*4
3mg./kg. CMI 18-3 35-3 24*0 10*9
10-3 42* 6 6*4 97*2
4* 6 23-2 11*5 77*9
3*8 13*3 14*3 38*2
AVERiiGE 9-3 28-6 14*1 56*1
3mg./kg. CSE 5*3 31*6 4*7 22*7
14-9 28*6 2*7 15*5
28'6 7-1 2*7 18*1
3*3 20*8 4*3 60'7
AVERAGE 12*8 22-0 3*6 29*3
3mg,/kg. CHS 13-8 11*5 3*2 83*3
6-2 100*0 6* 6 90*0
6“7 109*0 5-5 12*4
7"7 68*4 8*4 22*7
AVERilGE 8“ 6 72'2 5*9 52*1
103.
TABLE 10. (Contd.)
PHOTHROÎÜBIN
INITIAL
C0NSUÎ.CPTI0N INDEX PROTHROMIN CONSmïPTION INDEX 
2 HOURS AFTER 2 HOURS i\FTER 
INJECTION INITIAL INJECTION
P. ROTUNDUS 12;0 90*3 DEGRADED 8*2 142*0
3mg./kg. 8*9 104*0 EUCHENivIA 15-2 82*1
15 “8 235*4 200mg/kg. 10*1 79*8
14-0 154*5 19*0 111*0
AVERAGE 12*7 146*1 10*6 104*7
0*5 HOUR AFTEP 
INJECTION
0.5 HOUR AFTER 
INJECTION
HEPARIN 5*1 4*4 HEPARIN 3*6 51*5
75i,u.,/kg. 7*7 5*1 200 i,n,/kg 4*2 303*0
4*0 6*9 10*4 447*3
2*2 3*4 3*0 536*2
AVERilGE 4*8 5*0 5*3 334*5
m a u T A L 3 “ 6 4*1
(Control) 7*3 5*3
25mg./kg, 9*0
20*0
1*5
12*0
AVER/lGE 10*0 5*7
104.
GODS k m  
DOSE
TABLE 11 
THROMBOPLASTIN CrEPIEKiiTION TEST
k - CY 
5 mge/kg.
Initial 
2 Hours after 
Injection
tt It
it It
tt II
A -  CY 
5 mg./kg.
Initial 
2 Hours after 
Injection
t) II
tl tl
k - CMI
5mgc/kgc
Initial 
2 Hours after 
Injection
tl It
II It
II It
1.
2.
SUBSTRjVTE CLOTTING TIECES (iN SECS)
12,
1
43, 23, 12, 12 12,
l u
33, 38, 23, 15, 15, 
llz— 5.2? 4.2. 46, 32,
12
32, 21
12c
18,
15, 15, 15"
20
86, 34, 
âl2 .SU
43, 9,
14, 12, 10, 11, 10, 10c 
■L... 4 7 ^ Æ U U U _ 2 ^
6, 5, 4: 4
1 & - U U _ U U _ _ _ 2 8 ,   17, 15,
60, 17, 9, 8, 6, 6,
_6U_UU_.92, 81, 112, . 74., 45, 40,
6 c2c ^00, 35, 9, 8,
^22, 110, 120, 110, 85,
, 60, 25, 16, 14,3c
4o
1.
68
65, 36
45, 6, 5, 5, 5, 5? 4, 5,
25,
lU l.
6,
U
3S.L
5,
33 ,  2 6 ,  24 ,  23c 23
17,
27_._
5
12
5,
10,
4,
8c
5, 4,
3-2---11.
4, 5,
A
5
A
8 JL
4, 
7,
4.
8c
105
CODE AND 
DOSE SUBSTMTE CLOTTING TILDES (IN SECS.)
A- ®il
5 mg./kg.
Initial 
2 Hours after 
Injection
It
1, 11,
58,
6?
60,
4 ? 
46,
3,
26?
4 ,
24,
4,
17?
3?
16?
4.
16 c
n 2. 31, 5, 5, 4, 5, 4 ? 4, 4.
48, .51, 48, 53? 32, 21? 18, 22.
3,- 13, 7, 5, 4, 5, 4? 4 j 4.
46, U Q j 35? 21? 16, 14jL_, l/t? 11c
4c 23, 11, 9, 8, 8, 8, 8, 7.
70, 50, 45? 54? 55. 54,, 48, 51.
k - CSE 
5 mg./kg.
Initial 
2 Hours after 
Injection
I
1. 45,
50,
13,
27,
7,
18 y
6?
12,
6,
10,
5,
10?
6?
10,
5c
_ U
u 2* 20, 5, 4, 4, 4, 5, 5, 4.
29, 24, 15? 10, 9? 9? 8? 9c .
3. 18, 6, 6, 4, 5? 5, 5, 5.
50, 60, 55? 50_?. 37? 27? 26, 22.
I 4" 7, 5, 5, 5? 5? 5? 5? 5.
32, 30, 19i- __ll_
5,
80,
12y J U _
5,
92?
_ 1 U _
5,
85?
12.
Soln.
X- CSE 
5 mg./kg,
tl
Initial 
2 Hours after 
Injection
It
1, 12,
87,
6,
...92,.
5,
79?
5?
73?
6 0
70 c
2. 27, 8, 8? 7, 6, 7? 7? 7c
98, 38, 25? 30? 28? 23? 28, 28.
3e 55, 17, 7, 6, 6, 6? 6? 6,
9.0?.— 6.4.,. 80 y 67? 67? 64, 54? 43.
I It
4" 30, 9, 6, 6, 6? 5? 5, 5c
97? 75? 55? 63? 54? 56, 48? 30.
106,
TABLE 11 (Contd.)
GOBE Aîœ 
DOSE SUBSTE/lTE CLOTTING TlIffiS (lll SECS.)
k - CNS 
5 mg./kg.
Initial 
2 Hours after 
Injection
I
1. I25.
37,
6,
36,
5,
17,
4,
12,
4, 
9i
3 ? 
10,
4,
10,
4^
10.
tt 2. 27, 6, 5, 4, 4, 4, 4 ? 4 .
37, 35, 25, 22, ...14.3 . 14, 14? 15-.
I
3, 30, 7, 7, 7, 7. 6, 63 6.
46, 11, 8, 6,, 6, ......63^ 6, 6.
I
4» 34, 7, 5, 4, 5, 4, 4, 4.
48, 23, 14, 13, 12, 11, 11, 12.
A- CHS
5 ing./kg.
(l result 
only)
Initial 
2 Hours after 
Injection-
33,
75,
9,
60,
8,
55,
6,
31,
6,
30,
63
25,
5,
24,
6.
28.
k - CY 
3 mg./kg.
Initial 
2 Hours after 
Injection
1. 15,
34,
7,
24,
6,
26,
5,
15,
5,
12,
5,
12,
4,
12,
5.
13,
2. 35, 7, 6, 6, 5, 5, 5, 5.
40, . 27, 15, 11, 12, 11? 11, 11.
3. 34, 12, 10, 9, 83 7, 7, 7-
24, 15, . 9, 10, , 9,3_ , 9, 8, 8. 1
t t I 4. 28, 7, 5, 4, 4. 5, 4, 4.
44, 35, 16, 10, 12, 11,. 1 ^ 12.
À- CY
3 rag/kg.
Initial 
2 Hours after 
Injection
1
1. 7,
40,
6,
41,
5,
28,
4 9 
22,
4 3 
19,
A|. y
17,
4 3 
18,
4.
19.
I t
2« 16, 7, 5, 5, 4? 4 3 4, 4.
39, 34 7 23, 19, 15, 16, 15.?,^, 16.
I 1 3. 36, 20, 9, 7, 6, 63 5, 5-
39, 51, 52, 47, 36, 22, 16, 13.
I I t 30, 12, 8, 6, 5, 5, 4 ? 5.
73, -ilju 62, 65, 43, 33, 20, 16.
107.
TABLE 11 (Contd.)
CODE AND
DOSE
k - CMl 
3 mg./kg.
X- CMl 
3 mg./kg.
Soln. 
k - CSE 
3 mg,/kg.
Initial 
2 Hours after 
Injection,
1
SUBSTHilTE CLOTTING TIMS (IH SECS.)
9,
Initial 
2 Hours after 
Injection
Initial 
2 Hours after 
Injection,
36, 15,
38, 6,
42, 13,
3.
4.
2.
4
l6 , 8,
20,
If
7,
n
6,
8,
a
If
If
8 ,
7,
%
8 ,
8, If
3 ^
9.
8
8 ,
8 ,
8,
13,
6,
8, 8
6,
If
a
6,
8,
If 7. 
8,
6, 6, 
6, 8.
18, 7 7, 7 7 8,
.7.0, 51, 193 23, 16, 20
If 
l6,
7
XL
31, 12, 10, 9, 9, 8, 8, 9.
65, 60, 60, 47, 29, 23. 17, 17-
40, 9, 8, 7, 7, 7, 7, 7.
135^.. 95, 23, 19, 15, 16, 15, l6.
21 6
40, 40, 15, 13, 13
7 3 3 3 3 3 4 ?
44? 40 3 13 9. ,10
63 6, 4 3 4 3 4 3 5, 4 3 4
48,....40.3 38, 20,...15, 20, 15, 16
45, 20
48, 21,
10,
8,
9, If
i.
63
6 0
6 c 
8.
32, 8 5, 4, '-t 9 4, 3,
I 84 , 54, 21, 15, 11, 11, 11
4,
10
I&BLB 11 (Contd.)
108.
CODE AND
DOSE SUBSTRilTE CLOTTING TIMS (IN SECS.)
Soln.
A- CSE 
3 mg./kg.
u
Initial 
2 Hour after 
Injection
I t
1. 37? 
66,
10,
49?
7? 
60 9
7?
62,
6,
41,
6,
40,
6,
.,26,
6.
26.
2. 49, 23, 10, 8, 9, 8, 7, 8.
65 9 91? 60, 48, 68, 56, 45, 31-
tl I t 3.
36, 8, 3? 4? 3, 3, 4, 4 •
29? 9? __6, 7. 7, j 7 7-
I t I t
4, 26, 63 5, 5, 5, 4, 4, 5-
45? 53? 45, 35, 20, 15, 16, 15-
k - CITS 
3 mg./kg.
Initial 
2 Hours after 
Injection.
I t
1. 36,
70,
8,
78,
7?
30,
7?
16,
6,
16,
6, 
16,
6,
15,
7.
17- _
t i
2. 8, 5, 8, 7, 7, 7, 7, 7.
13? 8, 8, 9, 8, 8, 9, . 9.
I t I t
3o 6, 6, 6, 5, 5, 6, 63 6.
33? 24, 17? 17? 11? 17?
I t I t
4, 71, If 6, 6, 6, 6, 6, 6.
66 9 60, 35, 16, 159 143 17, 15,
A- CNS 
3 mg./kg.
Initial 
2 Hours after 
Injection
1
1. 11,
37?
6,
- 4-Q..Î ,
5?
31,
4,
32,
4,
27,
4 ? 
22,
5,
20,
4 *
24.
I I
2. 19? 11? 9, 9? 7, 8, 63 8.
32? 30, 35? 35, 38, 34, 313 28.
tt I I 3. 15, 12, 6, 5, 5, 4, 5? 4 «
36, 21, 17? 16, 14, 16, 15? _15.?. /
I I I I
4. 18, 65 5, 5 , 4, 4, 5 , 4 '
36? 32, 22 , 16, 16, 16, 17? 16.
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TABLE 11 (Contd.)
GOBE ABB
DOSE
P. SOTDKDUS 
3 mg./kg.
Initial 
2 Hours after 
Injection
DEGRADED 
EUCHEHMA 
GARRAGEBim 
200 mg,/kg.
Initial 
2 Hours after 
Injection
SÜBST.BATE CLOTTING TIMS (IN SECS.)
HEPARIN 
75 l.U./kg,
Initial
J- Hour^ after
Injection
1560,
80_
14? If 
77, 55,
4»
34?
97^
9?
8
7?
6
7 If
18,
If If 
18, 16,
7.
18,
7
16
If
l6.
6
2ÂJ.
6 
11 3
6, 6 
13_9___13
6
lA
If
60^
3 6
4 2
89
58,
81l
22 :
68,
11,
lOli.
6, 6, 
9? 10,
10, 12,
5?
10,
12
A i
5 ,
10.-
12,
AA.
5 6 ,  5 5 ,  32
130 AL
If
9 2 ,
6  y 6  y
90
40?
A A l
42? 23
AO
12,
4 6 ,
12, 12, 
9 0 ,  5 0 ,
1 3 ,
AA.
7o
AA....
1 3 .
.AA_
26.1 9 ,  2 2 ,
9 1 ,  9 7 ,
1, 28
2 .  ; 4 3
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TABLE 11 (Contd.)
CODE AND 
DOSE SUBSTRATE CLOTTING TIMES (iN SECS.)
liBPASIH 
200 l,ïï./fcg.
Initial
-g: Hour, after
Injection
I t
1. 31?
49,
7,
50,
5,
45,
5,
42,
5,
44?
5,
48,
4,
423
4-
50.
I t 2. 65, 44, 14, 9, 9, 7, 8, 7.
32, 32, 49, 36, 39, 36, 39, 32.
I t I 3: 25, 6, 5, 5, 4, 4, a ?
40? 42, 41, 33, 35, 29, 365 29-
11
4. 30 y 1 0 , 6, 5, 5, 4, 4, 5.
33, 25, 32, 30, 27, 37, 37, 32.
NEMBUTAL
(Control)
Initial
after
Injection,
1, 2 0  y  
1 0 ,
6,
5,
4,
.4.,... .
3,
4 ,
4 ? 
4,
4,
4,
3,
4,
4-
4 .
2 , 60, 9, 7, 7, 7, 7, 6, 6,
16,. 7? 6, 6, 6, 6, ...... 6, 6.
3- 35, 9, 6, 5, 5, 5, 4 , 4.
30, 1 1 , 7, 5, 5, 5, 4 , 4 .
t t I
4 . 31, 6? 5, 5, 4 , 4 , 4 , 4 ,
18, 4 , 4 , 4, 3, 4, 4o
Ill
TABLE 12
PL/i-TELBT COUNTS (iH VITRO) 
IN THOUSilNDS/cu.nim. BLOOD.
I/o
CONCMTRATION OF 
0*5f^  O'l^ o
CARRAGEENS
0*05% 0*01 b^
k - CY 109 122 135 83 65
A - GY 223 142 186 95 80
FOIiYIDES ROTUHDÜS 108 184 166 217 113
DEGMDBD EUCHEMA 370 352 347 359 299
HEPARIN 431 348 433 473 383
CONTROL PLATELET COUNTS
Rabbit No. Count
120B 373, 421, 394, 397, 294, 380.
122B 310, 250, 410, 394-
128B 380.
130B 444
112,
TABLE 12A
OQMPiiHISON AT APPROXIMTE PHYSIOLOGICAL CONCEHTEATIOITS
SUBSTANCE
k " CY 
A " CY
POLYIBES ROTüNDUS 
DEGRADED EÏÏCHEÎJMA 
HEPARÎN
CONCENTRIiTION
0*01/
O-OBc
O'Ol/ 
0 014
PLATELET COUNT
65
80
113 
352 
383
TABLE 12B 
PLATELET COUNTS (iN YIYO)
SUBSTMCE 
k - CY
- GY
COAGn. TIME 
10 mins.
DEGRADED EUCHEUT/iA 
(4 RaUMts)
14 mins.
15-20 mins.
PLATELET COUNT 
210
60
300-350
COMMENTS
Considerable 
agglut inat i on.
No severe toxic 
symptoms apparent. 
Survived.
No agglutination 
observed.
Pew free platelets 
Rabbit severely 
dyspnoeic, 
died overnight.
No agglutination 
observed.
Normal free plate­
lets.
Non-toxic.
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TiûBLE 1 3
FIBRINOGEN - CiiEPL/).GBENAN REACTIONS
CONCENTRATION OF CARRAGEENM (mg/ml)
CMRAGEENAN
0 - 625 0-313 0-157 0*079 0*04 0'02 0-01 0-005
GY X -CAKRAGOTAN — — - + tl t+t
CNS " - - - 0 0 ++ ttt
CSE ” — - - 0 + 11
CMl " — “ "■ — - 0 0
POLYIDES ROTUNDNS - - — 0 1 11
GY k-GARRACEENAN. *** ». 0 + • + + ■ i
CNS " — 0 0 0 + + t + 1
CSE '* “ - — - “ “ 0 0 1
CMl " - - - ” — — 0 0
HEPARIN *' — - - “ 0
“ 1
3 “13 1*57 0-79 0-40 0*20 o'-10 0-05 0-025
DEGRADED EUCHEUtlA 
CARRAGEENim — - — -
clearing of opalescent solution 
0 no observable effect 
+ precipitate formed 
-H-+ marked precipitation
X - carrageenans and Polyides gave granular precipitates 
k - carrageenans gave colloidal precipitates.
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THROMBIN GENERATION TEST*
Chondrus crispus (A -GMI) 5mg./kgo
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